[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 116
1. Friedrich RE, Hartmann M, Mautner VF: Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children. Anticancer Res; 2007 Jul-Aug;27(4A):1957-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
  • BACKGROUND: Malignant peripheral nerve sheath tumors (MPNST) constitute a heterogeneous group of malignant tumors that probably arise from cells of the peripheral nerve sheath.
  • Association of MPNST with neurofibromatosis type 1 (NF1) is frequently reported.
  • MPNST contribute significantly to the reduced life-span of NF1-patients.
  • At present there are only sparse data on MPNST in NF1-children.
  • The aim of this study was to determine the outcome of children affected with NF1 who developed an MPNST.
  • MATERIALS AND METHODS: Over the period of 1985 to 2005, we followed 52 NF1 patients with MPNST at our outpatient department.
  • RESULTS: Out of this cohort, 8 patients with MPNST were aged 1 to 17 years at the time of MPNST diagnosis (mean age: 12 years; 5 girls and 3 boys).
  • We noticed the following characteristics: MPNST arose from plexiform neurofibromas (PNF) with invasive or displacing growth pattern on MRI.
  • Diagnosis of MPNST in this age group took longer compared to adults.
  • This cohort did not show longer survival periods than adults with MPNST.
  • The longest survival of 112 months was achieved for a girl who presented with MPNST of the distal upper arm and underwent amputation.
  • The NF1 mutation analysis in the MPNST pediatric age group revealed the same mutational spectrum as the adult group.
  • CONCLUSION: Our data reveal MPNST in children with NF1.
  • [MeSH-major] Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649804.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


2. Melean G, Hernández AM, Valero MC, Hernández-Imaz E, Martín Y, Hernández-Chico C: Monozygotic twins with Neurofibromatosis type 1, concordant phenotype and synchronous development of MPNST and metastasis. BMC Cancer; 2010;10:407
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monozygotic twins with Neurofibromatosis type 1, concordant phenotype and synchronous development of MPNST and metastasis.
  • The condition predisposes individuals to the development of malignant nervous system tumours, most frequently Malignant Peripheral Nerve Sheath Tumours (MPNSTs).
  • Both twins developed a left sciatic plexiform neurofibroma that evolved into MPNST at a similar age and they also developed pulmonary metastasis at the same age.
  • [MeSH-major] Lung Neoplasms / secondary. Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / pathology. Twins, Monozygotic
  • [MeSH-minor] Adult. Genotype. Humans. Male. Mutation / genetics. Neurofibromin 1 / genetics. Phenotype. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet A. 2006 Oct 1;140(19):2080-4 [16770809.001]
  • [Cites] Am J Hum Genet. 2007 Jan;80(1):140-51 [17160901.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Feb;4(2):130-4 [17259933.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Pediatrics. 2009 Jan;123(1):124-33 [19117870.001]
  • [Cites] Acta Chir Belg. 2009 Jan-Feb;109(1):123-5 [19341215.001]
  • [Cites] Hum Mol Genet. 2009 Aug 1;18(15):2768-78 [19417008.001]
  • [Cites] EMBO Mol Med. 2009 Jul;1(4):236-48 [20049725.001]
  • [Cites] Hum Mutat. 2010 Jun;31(6):E1506-18 [20513137.001]
  • [Cites] Hum Mutat. 2008 Aug;29(8):E103-11 [18484666.001]
  • [Cites] Neurogenetics. 2010 Oct;11(4):391-400 [20358387.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Dec;136(12):1869-80 [20229272.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):790-818 [10712197.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):359-69 [10862044.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Feb;133(1):24-8 [11890985.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Genet Epidemiol. 2002 Aug;23(2):150-64 [12214308.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):555-61; discussion 571-2, 646-51 [12403553.001]
  • [Cites] Hum Genet. 2003 Mar;112(3):289-97 [12596053.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Am J Hum Genet. 1993 Aug;53(2):305-13 [8328449.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5677-80 [7585653.001]
  • [Cites] Hum Genet. 1997 Jun;99(6):720-6 [9187663.001]
  • [Cites] Fam Cancer. 2005;4(4):323-33 [16341812.001]
  • (PMID = 20687928.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ PMC2924852
  •  go-up   go-down


3. Friedrich RE, Kluwe L, Fünsterer C, Mautner VF: Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. Anticancer Res; 2005 May-Jun;25(3A):1699-702
Genetic Alliance. consumer health - Peripheral type neurofibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
  • About 10% of patients with NF1 develop malignant peripheral nerve sheath tumors (MPNST), usually arising from PNF, and this is the major cause of poor prognosis.
  • Our objective was to establish magnetic resonance imaging (MRI) criteria for MPNST, and to test their usefulness in detecting early malignant changes in PNF and to correlate the findings with the mutations of the NF1 gene.
  • The study was approved by the Institutional Review Board and all patients gave informed consent to analyze clinical records and tumor material for scientific purposes.
  • RESULTS: MRI was performed on 50 patients with NF1 and nerve sheath tumors, of whom 7 had atypical pain, tumor growth or neurological deficits indicative of malignancy; the other 43 were asymptomatic.
  • All 3 asymptomatic patients with inhomogeneous lesions were shown to have MPNST.
  • Analysis of mutations of the NF1 gene of the 10 MPNST patients revealed a variety of mutations.
  • Concerning the correlation of genetic findings and MPNST in NF1, the sample size of this study group was too small to define genotype-phenotype relations.
  • CONCLUSION: This study provides evidence for certain radiographic findings on MRI in PNF of NF1 patients that have to be considered as signs of malignancy, in particular indicating an MPNST.
  • [MeSH-major] Genes, Neurofibromatosis 1. Mutation. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033085.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Murovic JA, Charles Cho S, Park J: Surgical strategies for managing foraminal nerve sheath tumors: the emerging role of CyberKnife ablation. Eur Spine J; 2010 Feb;19(2):242-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for managing foraminal nerve sheath tumors: the emerging role of CyberKnife ablation.
  • Sixteen Stanford University Medical Center (SUMC) patients with foraminal nerve sheath tumors had charts reviewed.
  • Parameters were evaluated for 16 foraminal nerve sheath tumors undergoing surgery, some with CyberKnife.
  • The malignant peripheral nerve sheath tumor (MPNST) had prior field-radiation and adds another case.
  • The MPNST had a hemi-laminotomy then laminectomy/total facetectomy/fusion, followed by CyberKnife.
  • Of 11 single-operation-peripheral nerve sheath tumors, the asymptomatic case remained stable, nine (92%) improved and one (9%) worsened.
  • The MPNST had presentation improvement after the first operation, worsened and after the second surgery and CyberKnife, the patient expired from tumor spread.
  • In conclusion, surgery is beneficial for pain relief and function preservation in foraminal nerve sheath tumors.
  • [MeSH-major] Laminectomy / methods. Nerve Sheath Neoplasms / surgery. Radiosurgery / methods. Spinal Neoplasms / surgery. Spinal Nerve Roots / surgery. Spine / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dura Mater / pathology. Dura Mater / radiography. Dura Mater / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Radiotherapy / methods. Retrospective Studies. Spinal Canal / pathology. Spinal Canal / surgery. Survival Rate. Thoracotomy / methods. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1995 Jun;82(6):917-23 [7760192.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):572-7 [7897516.001]
  • [Cites] Skeletal Radiol. 1995 Aug;24(6):458-61 [7481906.001]
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):67-74; discussion 74-5 [8747953.001]
  • [Cites] J Neurosurg Spine. 2007 Dec;7(6):587-93 [18074682.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):294-300 [8869056.001]
  • [Cites] Clin Orthop Relat Res. 1996 Apr;(325):251-5 [8998885.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Apr;37(4):354-7 [9136563.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):813-20; discussion 820-2 [9316042.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):279-89; discussion 289-90 [9482178.001]
  • [Cites] J Neurosurg. 1998 May;88(5):898-902 [9576261.001]
  • [Cites] Eur J Cell Biol. 1998 Apr;75(4):321-30 [9628318.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):430-3 [10070446.001]
  • [Cites] Neuroradiology. 1999 Sep;41(9):625-9 [10525761.001]
  • [Cites] Surg Gynecol Obstet. 1952 Feb;94(2):161-72 [14901250.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):291-318 [15527097.001]
  • [Cites] Neurosurgery. 2005 Mar;56(3):510-5; discussion 510-5 [15730576.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1411-2 [15797097.001]
  • [Cites] Clin Neurol Neurosurg. 2005 Jun;107(4):318-24 [15885392.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] Expert Rev Neurother. 2005 Jul;5(4):515-23 [16026235.001]
  • [Cites] J Neurosurg Spine. 2005 Jul;3(1):1-11 [16122015.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):53-61 [16087703.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4):674-85; discussion 674-85 [16575331.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 29;348(3):971-80 [16908010.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1485-92 [16797490.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Feb 1;25(3):286-91 [10703098.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):187-90 [10903595.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • [Cites] J Spinal Disord. 2001 Feb;14(1):79-83 [11242279.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):210-5 [11302622.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Spinal Disord Tech. 2002 Dec;15(6):507-12 [12468979.001]
  • [Cites] J Neurosurg. 2003 Jul;99(1 Suppl):121-4 [12859072.001]
  • [Cites] Clin Anat. 2003 Sep;16(5):404-10 [12903062.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Jan 1;29(1):E10-4 [14699292.001]
  • [Cites] Eur J Radiol. 2004 May;50(2):159-76 [15081130.001]
  • [Cites] Neurol India. 2004 Sep;52(3):319-24 [15472419.001]
  • [Cites] J Neurosurg. 1968 Mar;28(3):191-203 [5643912.001]
  • [Cites] J Bone Joint Surg Am. 1983 Sep;65(7):992-7 [6885878.001]
  • [Cites] Ann Thorac Surg. 1983 Oct;36(4):402-7 [6625735.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):686-90 [6590800.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;47(4):291-301 [6151310.001]
  • [Cites] Radiology. 1985 Apr;155(1):143-6 [3975392.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):276-82 [3392571.001]
  • [Cites] Brain. 1988 Dec;111 ( Pt 6):1355-81 [3145091.001]
  • [Cites] Ann Intern Med. 1990 Jul 1;113(1):39-52 [2112353.001]
  • [Cites] J Bone Joint Surg Br. 1990 Sep;72(5):904-7 [2211781.001]
  • [Cites] J Neurosurg. 1991 Feb;74(2):248-53 [1846409.001]
  • [Cites] Neurology. 1991 Dec;41(12):1923-7 [1745350.001]
  • [Cites] Neurochirurgie. 1991;37(6):388-93 [1780017.001]
  • [Cites] Am J Hum Genet. 1992 Sep;51(3):486-96 [1496982.001]
  • [Cites] Surg Neurol. 1993 Dec;40(6):504-7 [8235975.001]
  • [Cites] Neurosurg Rev. 1994;17(1):43-9 [8078608.001]
  • [Cites] Clin Neurosurg. 1994;41:204-23 [7842604.001]
  • [Cites] Ann Thorac Surg. 1995 Feb;59(2):469-72 [7847968.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):621-6 [7674010.001]
  • (PMID = 19798517.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899818
  •  go-up   go-down


5. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M: Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol; 2010 Dec;136(12):1869-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
  • OBJECTIVE: Neurofibromatosis type 1 (NF1) patients have a 13% risk of developing a malignant peripheral nerve sheath tumor (MPNST).
  • Many MPNSTs are histopathologically complex, with regions exhibiting features of the original benign plexiform neurofibroma (PNF), of an atypical PNF, or of MPNST showing varying degrees of de-differentiation.
  • This study analyzed the genetic alterations associated with this pathological heterogeneity in order to identify the genetic processes involved in transformation from a benign to an aggressive malignant tumor.
  • METHODS: A histological and molecular analysis of a single MPNST tumor that was subdivided into three histopathologically distinct regions, a benign PNF (region 1), an atypical PNF (region 2), and a high-grade MPNST (region 3), was carried out.
  • Tumor DNA from each region was analyzed in conjunction with the patient's lymphocyte DNA.
  • The NF1-associated LOH analysis found that LOH increased in the three tumor areas, with 9, 42, and 97% LOH evident in regions 1, 2, and 3, respectively.
  • Additional genetic changes, including losses of TP53, RB1, CDKN2A, and of several oncogenes and cell-cycle genes, were found only in the malignant MPNST (region 3).
  • DISCUSSION: This is the first study that correlates the histological and molecular changes associated with MPNST development, confirming the significant cellular and genetic heterogeneity that poses both diagnostic and therapeutic challenges.
  • [MeSH-major] Nerve Sheath Neoplasms / genetics. Neurofibroma / genetics. Neurofibromatosis 1 / genetics. Neurofibromin 1 / genetics
  • [MeSH-minor] Adult. Base Sequence. Comparative Genomic Hybridization. DNA Mutational Analysis. Disease Progression. Germ-Line Mutation. Humans. Loss of Heterozygosity. Male. Molecular Sequence Data


6. Kim JG, Sung WJ, Kim DH, Kim YH, Sohn SK, Lee KB: Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass. Korean J Intern Med; 2005 Mar;20(1):100-4
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass.
  • A malignant peripheral nerve sheath tumor (MPNST) is an extremely rare soft tissue tumor in the general population.
  • On the other hand, there is a higher incidence of MPNST in patients with neurofibromatosis type I (von Recklinghausen's disease).
  • This paper reports two patients, a 31 year-old woman with multiple neurofibromatosis presenting as an intraabdominal malignant peripheral nerve sheath tumor, and a 33 year-old woman with an intrathoracic malignant peripheral nerve sheath tumor.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / complications. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Peripheral type neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] J Neurosurg Sci. 1989 Jul-Sep;33(3):253-7 [2614511.001]
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):126-9 [6766081.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Jul 27;383(1):43-57 [157612.001]
  • [Cites] Cancer. 1977 May;39(5):1955-8 [858125.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Korean J Intern Med. 2001 Sep;16(3):201-4 [11769579.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Cancer. 1963 Aug;16:1015-27 [14050005.001]
  • [Cites] Scand Cardiovasc J. 1998;32(3):173-5 [9764434.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1996 Jun;44(6):864-8 [8753103.001]
  • [Cites] Science. 1990 Jul 13;249(4965):181-6 [2134734.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1617-27 [6796886.001]
  • (PMID = 15906964.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891405
  •  go-up   go-down


7. Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page GP, Worley PF, Aronow BJ, Schorry EK, Ratner N: Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res; 2010 Oct 15;16(20):5048-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • pNF can undergo transformation to malignant peripheral nerve sheath tumors (MPNST).
  • There are no identified serum biomarkers of pNF tumor burden or transformation to MPNST.
  • Serum biomarkers would be useful to verify NF1 diagnosis, monitor tumor burden, and/or detect transformation.
  • EXPERIMENTAL DESIGN: We used microarray gene expression analysis to define 92 genes that encode putative secreted proteins in neurofibroma Schwann cells, neurofibromas, and MPNST.
  • ADM protein concentrati on was further elevated in serum of a small sampling of NF1 patients with MPNST.
  • MPNST cell conditioned medium, containing ADM and hepatocyte growth factor, stimulated MPNST migration and endothelial cell proliferation.
  • ADM serum levels do not seem to correlate with the presence of pNFs but may be a biomarker of transformation to MPNST.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20739432.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K01 NS049191; United States / NINDS NIH HHS / NS / R01 NS028840; United States / NINDS NIH HHS / NS / K01-NS049191
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Culture Media; 0 / RNA, Messenger; 148498-78-6 / Adrenomedullin
  • [Other-IDs] NLM/ NIHMS763673; NLM/ PMC4837895
  •  go-up   go-down


8. Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA: DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol Cancer; 2008;7:48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
  • BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are rare and highly aggressive soft tissue tumors showing complex chromosomal aberrations.
  • In order to identify recurrent chromosomal regions of gain and loss, and thereby novel gene targets of potential importance for MPNST development and/or progression, we have analyzed DNA copy number changes in seven high-grade MPNSTs using microarray-based comparative genomic hybridization (array CGH).
  • CONCLUSION: Our study shows the potential of using DNA copy number changes obtained by array CGH to predict the prognosis of MPNST patients.
  • [MeSH-major] DNA, Neoplasm / analysis. Gene Dosage. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Nerve Sheath Neoplasms / genetics. Oligonucleotide Array Sequence Analysis. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adenovirus E1A Proteins / genetics. Adult. Aged. Amino Acid Oxidoreductases / genetics. Antigens, Neoplasm / genetics. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 8. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Expression Regulation, Enzymologic. Humans. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / genetics. Middle Aged. Neoplasm Proteins / genetics. Prognosis. Proto-Oncogene Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] BMC Bioinformatics. 2004 Jun 9;5:74 [15189572.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1172-8 [15509679.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):793-8 [7790113.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Sep;14(1):8-14 [8527390.001]
  • [Cites] Monogr Pathol. 1996;38:129-61 [8744276.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jul;25(3):205-11 [10379866.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):323-31 [10398425.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):362-9 [10398430.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):1-6 [10469430.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Oct;26(2):151-60 [10469453.001]
  • [Cites] Bioinformatics. 2005 Mar15;21(6):821-2 [15531610.001]
  • [Cites] Mutat Res. 2005 Aug 25;576(1-2):22-38 [15878778.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):297-303 [16391845.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8984-93 [16982739.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Trends Mol Med. 2006 Dec;12(12):580-7 [17071139.001]
  • [Cites] J Orthop Res. 2007 Jan;25(1):116-21 [17034065.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):187-92 [17111191.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):644-55 [17394133.001]
  • [Cites] J Pathol. 2000 Jan;190(1):31-8 [10640989.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):181-90 [10822134.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1657-66 [12670920.001]
  • [Cites] J Pathol. 2003 Aug;200(5):568-76 [12898592.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Carcinogenesis. 2004 Mar;25(3):325-32 [14604892.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • (PMID = 18522746.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / ETV4 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / LOXL2 protein, human; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2442610
  •  go-up   go-down


9. Pusceddu S, Bajetta E, Buzzoni R, Carcangiu ML, Platania M, Del Vecchio M, Ditto A: Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report. Int J Gynecol Pathol; 2008 Oct;27(4):596-600
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report.
  • A rare variant of malignant melanoma (MM) of the uterine cervix that mimics a malignant peripheral nerve sheath tumor (MPNST) is described.
  • Neoadjuvant chemotherapy and total abdominal hysterectomy and bilateral salpingo-ovariectomy plus pelvic lymphadenectomy were performed, and the diagnosis was MPNST, FIGO IIB.
  • A pathological review was obtained in our institution by a gynecological pathologist, who defined the primary neoplasm in the cervix as an MM, with a pattern of growth histologically simulating an MPNST, metastatic to the vagina.
  • To our knowledge, this is the first report in literature of MM of the uterine cervix resembling MPNST.
  • Despite its rarity, this variant of MM should be considered when a diagnosis of cervix MPNST is made.
  • [MeSH-major] Melanoma / pathology. Nerve Sheath Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Histocytochemistry. Humans


10. Fauth C, Kehrer-Sawatzki H, Zatkova A, Machherndl-Spandl S, Messiaen L, Amann G, Hainfellner JA, Wimmer K: Two sporadic spinal neurofibromatosis patients with malignant peripheral nerve sheath tumour. Eur J Med Genet; 2009 Nov-Dec;52(6):409-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two sporadic spinal neurofibromatosis patients with malignant peripheral nerve sheath tumour.
  • We analyzed two unrelated male patients in whom neurofibromatosis type 1 (NF1) was not suspected until they presented with malignant peripheral nerve sheath tumours (MPNSTs) in their thirties and forties, respectively.
  • Patient A presented with progressive peroneus paresis due to a rapidly growing MPNST in the thigh.
  • MRI examination revealed multiple symmetrical spinal neurofibromas in this patient as well as in patient B who presented at the age of 42 with paraparesis and an MPNST at spinal level L4.
  • To our knowledge these are the first MPNST patients with the clinical phenotype of SNF.
  • The clinical course observed in these two patients suggests that nodular plexiform neurofibromas and spinal-nerve-root neurofibromas which may be asymptomatic for a long time and, hence, unrecognized in SNF patients bear the risk for malignant transformation.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Base Sequence. DNA Primers. Genes, p53. Humans. Hybrid Cells. Loss of Heterozygosity. Magnetic Resonance Imaging. Male. Mutation. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665063.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


16. Moon SJ, Lee JK, Seo BR, Kim JH, Kim SH, Lee KH, Lee MC: An intraosseous malignant peripheral nerve sheath tumor of the cervical spine: a case report and review of the literature. Spine (Phila Pa 1976); 2008 Sep 1;33(19):E712-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intraosseous malignant peripheral nerve sheath tumor of the cervical spine: a case report and review of the literature.
  • OBJECTIVES: To report a rare case of intraosseous malignant peripheral nerve sheath tumors (MPNST), and review the pertinent medical literature.
  • SUMMARY OF BACKGROUND DATA: The spinal MPNST that develops from spinal nerve roots and secondary bony erosion is well-known entity.
  • Complete excision of the tumor and posterior stabilization were performed through a posterior approach.
  • The tumor was noted to originate from the posterior element of C7.
  • RESULTS: The histopathology was diagnostic for a MPNST.
  • CONCLUSION: We report an intraosseous MPNST of the cervical spine.
  • MPNST should be added to the differential diagnosis of primary bone tumors causing spinal cord compression.
  • [MeSH-major] Cervical Vertebrae / pathology. Nerve Sheath Neoplasms / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. S100 Proteins / metabolism. Spinal Cord Compression / etiology. Spinal Cord Compression / pathology. Vimentin / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758353.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Ki-67 Antigen; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


17. Maldonado AR, Klanke C, Jegga AG, Aronow BJ, Mahller YY, Cripe TP, Crombleholme TM: Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med; 2010 Jul;12(7):613-23
National BioResource Project. culture/stock collections - NBRP resources .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Expression profile analyses of midkine (MDK), a multifunctional protein important in development but repressed postnataly, indicate that it is highly expressed in approximately 80% of adult carcinomas and many childhood cancers including malignant peripheral nerve sheath tumors (MPNST).
  • RESULTS: Tissue-specific MDK promoter activity in human tumor cells and transgene biological activity was confirmed in human MPNST tumor cells.
  • In vitro replication and cytotoxicity in human fibroblasts and MPNST cells by plaque and MTT assays showed that oHSV-MDK-34.5 increased replication and cytotoxicity compared to oHSV-MDK-Luc.
  • By contrast, no significant difference in cytotoxicity was detected between these viruses in normal human fibroblasts. oHSV-MDK-34.5 impaired in vivo tumor growth and increased median survival of MPNST tumor-bearing nude mice.
  • CONCLUSIONS: The transcriptional targeting of HSV lytic infection to MDK-expressing tumor cells is feasible. oHSV-MDK-34.5 shows enhanced anti-tumor effects both in vitro and in vivo.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 John Wiley & Sons, Ltd.
  • (PMID = 20603890.001).
  • [ISSN] 1521-2254
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA133663; United States / NCI NIH HHS / CA / F31 CA132613-01; United States / NIDDK NIH HHS / DK / R01 DK072446; United States / NCI NIH HHS / CA / R01 CA114004; United States / NCI NIH HHS / CA / F31 CA132613; United States / NIDDK NIH HHS / DK / R01 DK074055
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MDK protein, human; 0 / Nerve Growth Factors; 0 / RNA, Small Interfering; EC 1.13.12.- / Luciferases
  •  go-up   go-down


18. Houreih MA, Eyden B, Deolekar M, Banerjee S: A case of fibroblastic low-grade malignant peripheral nerve sheath tumor--a true neurofibrosarcoma. Ultrastruct Pathol; 2007 Sep-Oct;31(5):347-56
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of fibroblastic low-grade malignant peripheral nerve sheath tumor--a true neurofibrosarcoma.
  • The authors report a case of low-grade retroperitoneal malignant peripheral nerve sheath tumor (MPNST) showing Schwannian and fibroblastic differentiation in individual tumor cells.
  • The tumor was detected in a 29-year-old male and posed diagnostic difficulty because of the unusual morphologic and immunophenotypic features.
  • Morphologic examination of the H&E sections revealed a rather circumscribed, highly vascular, moderately cellular spindle cell tumor.
  • There were satellite nodules outside the main tumor mass and low mitotic activity but no necrosis.
  • The tumor cells stained strongly and diffusely for both S-100 protein and CD34.
  • Although the capacity of MPNST to exhibit divergent differentiation is well known, fibroblastic differentiation is generally poorly and inconsistently documented.
  • The present case represents an unambiguous demonstration of the co-expression within individual tumor cells of Schwannian and fibroblastic differentiation in a low-grade MPNST.
  • [MeSH-major] Fibroblasts / pathology. Nerve Sheath Neoplasms / pathology. Neurofibrosarcoma / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Humans. Male. Microscopy, Electron, Transmission. S100 Proteins / analysis. Schwann Cells / ultrastructure

  • Genetic Alliance. consumer health - Neurofibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963184.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


19. Tucker T, Friedman JM, Friedrich RE, Wenzel R, Fünsterer C, Mautner VF: Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet; 2009 Feb;46(2):81-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumours can cause serious complications and can also progress to malignant peripheral nerve sheath tumours (MPNSTs), one of the leading causes of death among NF1 patients.
  • Biopsy showed the presence of an MPNST.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930997.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Allison KH, Patel RM, Goldblum JR, Rubin BP: Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis. Am J Clin Pathol; 2005 Nov;124(5):685-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis.
  • We reviewed the clinicopathologic features of 5 cases of malignant peripheral nerve sheath tumor (MPNST) manifesting in superficial locations associated with cutaneous neurofibromas (4 cases) or superficial peripheral nerve (1 case).
  • However, identification of a benign precursor or origin from a nerve may be the most definitive way to properly classify these rare lesions.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203275.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


21. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D: Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg; 2009 Jun;249(6):1014-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
  • OBJECTIVE: Improved staging systems for malignant peripheral nerve sheath tumor (MPNST) prognostication and management are needed.
  • Consequently, we sought to identify clinical, pathologic, and molecular predictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST.
  • METHODS: MPNST patients treated from 1986 to 2006 (n = 140) were identified; 72 had NF-1 syndrome and 68 did not.
  • Paraffin-embedded neurofibroma or MPNST blocks were assembled in a tissue microarray; marker expression was evaluated immunohistochemically.
  • The 5 years DSS for localized tumor patients was 35% for NF-1 patients and 50% for sporadic patients.
  • MPNST >or=10 cm at diagnosis, partial resection, and metastasis development were significant negative predictors of DSS; completely resected tumors that lacked S-100 immunoreactivity had a nearly 5-fold increased risk of developing distant metastasis.
  • Ki67, vascular endothelial growth factor, p53, and pMEK were over-expressed in MPNST compared with benign neurofibromas.
  • Only tumor size and nuclear p53 expression were found to be independent prognosticators for MPNST DSS in a multivariable analysis.
  • CONCLUSIONS: MPSNT is a markedly metastatic and aggressive poor prognosis tumor.
  • Multiple clinical, pathologic, and molecular markers identified in this study, coupled with findings from previous series, should be considered for an improved MPNST staging system useful for prognostic assessment and management decisions.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Nerve Sheath Neoplasms / metabolism. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Neurofibromatosis 1 / complications. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474676.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


22. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM: Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology; 2005 Jul 26;65(2):205-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between benign and malignant peripheral nerve sheath tumors in NF1.
  • OBJECTIVE: People with neurofibromatosis type 1 (NF1) have a 10% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST).
  • However, it is not known whether an individual's risk of developing an MPNST is associated with the burden of benign neurofibromas.
  • CONCLUSIONS: The observation that malignant peripheral nerve sheath tumors are strongly associated with internal plexiform neurofibromas suggests that patients with neurofibromatosis type 1 with these benign tumors warrant increased surveillance for malignancy.
  • [MeSH-major] Nerve Sheath Neoplasms / epidemiology. Neurofibroma, Plexiform / epidemiology. Neurofibromatosis 1 / epidemiology. Peripheral Nerves / pathology
  • [MeSH-minor] Adolescent. Adult. Comorbidity. Cross-Sectional Studies. Female. Follow-Up Studies. Humans. Life Expectancy. Logistic Models. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Prevalence. Prognosis. Risk Factors. Survival Rate. Tomography, X-Ray Computed / adverse effects. Tomography, X-Ray Computed / standards. Ultrasonography / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043787.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M: Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol; 2010 Jan;220(1):58-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
  • Malignant peripheral nerve sheath tumours (MPNSTs) are aggressive soft tissue tumours that occur either sporadically or in patients with neurofibromatosis type 1.
  • The malignant transformation of the benign neurofibroma to MPNST is incompletely understood at the molecular level.
  • We have determined the gene expression signature for benign and malignant PNSTs and found that the major trend in malignant transformation from neurofibroma to MPNST consists of the loss of expression of a large number of genes, rather than widespread increase in gene expression.
  • Subsequent microRNA profiling of benign and malignant PNSTs indicated a relative down-regulation of miR-34a in most MPNSTs compared to neurofibromas.
  • In vitro studies using the cell lines MPNST-14 (NF1 mutant) and MPNST-724 (from a non-NF1 individual) show that exogenous expression of p53 or miR-34a promotes apoptotic cell death.
  • In addition, exogenous expression of p53 in MPNST cells induces miR-34a and other miRNAs.
  • Our data show that p53 inactivation and subsequent loss of expression of miR-34a may significantly contribute to the MPNST development.
  • Collectively, our findings suggest that deregulation of miRNAs has a potential role in the malignant transformation process in peripheral nerve sheath tumours.
  • [MeSH-major] Genes, p53. MicroRNAs / metabolism. Nerve Sheath Neoplasms / genetics. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adult. Apoptosis / genetics. Cell Adhesion / genetics. Cell Proliferation. Cluster Analysis. Down-Regulation. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neurofibroma. Oligonucleotide Array Sequence Analysis / methods. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction / genetics. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - MPNST-724 (CVCL_AU20) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - MPNST-14 (CVCL_AU21) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Dec;155(6):1879-84 [10595918.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] Am J Med Genet. 2000 Aug 28;93(5):388-92 [10951462.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):219-31 [12676581.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):258-64 [15446580.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):250-5 [7522538.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2820-8 [15571966.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):65-75 [15652750.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4530-43 [15930270.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] Cell Cycle. 2007 Jul 1;6(13):1586-93 [17554199.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 [17875987.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11099-101 [18056431.001]
  • [Cites] Oncogene. 2008 Sep 4;27(39):5204-13 [18504438.001]
  • [Cites] Cell. 2008 Oct 31;135(3):437-48 [18984156.001]
  • [Cites] Nat Struct Mol Biol. 2009 Jan;16(1):23-9 [19079265.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):123-8 [19029138.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):725-36 [19246520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):106-14 [16258501.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):99-106 [16491069.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] Dev Cell. 2006 Oct;11(4):441-50 [17011485.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):240-6 [17255769.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):731-43 [17540598.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]
  • (PMID = 19890883.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA127003; United States / NCI NIH HHS / CA / P50 CA127003-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN34 microRNA, human; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS212333; NLM/ PMC4058327
  •  go-up   go-down


24. Rizvi S, Mehboob J, Asghar AH, Mateen A, Raza T, Hameed A: Omental caking: a rare manifestation of malignant peripheral nerve sheath tumour. J Coll Physicians Surg Pak; 2010 Aug;20(8):554-5
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental caking: a rare manifestation of malignant peripheral nerve sheath tumour.
  • Malignant peripheral nerve sheath tumour (MPNST) is a very rare tumour with an incidence of one per 100,000 and constitutes between 3 to 10% of all soft tissue sarcomas.
  • Most of the sarcoma involve the extremities and retroperitoneal regions.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / radiography. Omentum. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Abdominal Neoplasms / pathology. Adult. Humans. Inguinal Canal. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20688026.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


25. Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, Domanski HA, Mandahl N, Liestøl K, Smeland S, Danielsen HE, Mertens F, Lothe RA: Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol; 2009 Oct;11(5):514-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.
  • The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery.
  • We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1).
  • We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST.
  • For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002).
  • This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome.
  • Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Blotting, Western. Comparative Genomic Hybridization. Disease-Free Survival. Female. Gene Expression. Humans. Image Processing, Computer-Assisted / methods. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Software. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Monogr Pathol. 1996;38:129-61 [8744276.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):13-25 [11145248.001]
  • [Cites] Lab Invest. 2001 Jun;81(6):833-44 [11406645.001]
  • [Cites] Arch Dermatol. 2001 Jul;137(7):908-13 [11453810.001]
  • [Cites] J Clin Pathol. 2001 Aug;54(8):631-6 [11477120.001]
  • [Cites] Histopathology. 2001 Aug;39(2):187-97 [11493336.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):610-5 [12070601.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 15;136(2):113-20 [12237234.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1337-45 [14508395.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • [Cites] Anal Biochem. 1981 Apr;112(2):195-203 [6266278.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cancer. 1994 May 15;73(10):2499-505 [8174045.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):282-8 [8816583.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1443-9 [9414187.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):612-7 [9688181.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Pediatr Dev Pathol. 1999 Jul-Aug;2(4):377-84 [10347283.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Oct;26(2):151-60 [10469453.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):74-81 [15715087.001]
  • [Cites] Histopathology. 2006 Jan;48(1):42-50 [16359536.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):97-102 [16540739.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):524-32 [16554732.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):187-92 [17111191.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):463-6 [17327286.001]
  • [Cites] Neoplasia. 2007 Aug;9(8):671-7 [17786186.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1855-60 [10595915.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1879-84 [10595918.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1885-91 [10595919.001]
  • [Cites] J Pathol. 2000 Jan;190(1):31-8 [10640989.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):250-5 [7522538.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):65-73 [7815081.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):793-8 [7790113.001]
  • [Cites] Virchows Arch. 1995;427(1):19-26 [7551341.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):202-6 [11135438.001]
  • (PMID = 19182148.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2765341
  •  go-up   go-down


26. Al Akloby O, Bukhari IA, El-Shawarby M, Al Mulhim F: Malignant peripheral nerve sheath tumor of the skin: case report. Am J Clin Dermatol; 2006;7(3):201-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the skin: case report.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors derived from Schwann cells or pluripotent cells of the neural crest.
  • In this report, we describe a 21-year-old Saudi woman who presented with an asymptomatic, solid, round, protruding tumor on the right upper back which was diagnosed as an MPNST with no stigmata of neurofibromatosis.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Back. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734508.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


27. Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O'Doherty M: [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol; 2008 Feb;19(2):390-4
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
  • BACKGROUND: Malignant peripheral nerve sheath tumours (MPNSTs) are difficult to detect in neurofibromatosis 1 (NF1) individuals.
  • The purpose was to evaluate [(18)F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) and PET computed tomography (CT) as a diagnostic tool for MPNST in NF1 patients with symptomatic plexiform neurofibromas and to verify the diagnosis by pathology and clinical follow-up.
  • Qualitative FDG PET and PET CT associated with semi-quantitative maximum standard uptake value (SUVmax) assessed possible malignant change.
  • RESULTS: In all, 116 lesions were detected in 105 patients aged 5-71 years, including 80 plexiform neurofibromas, five atypical neurofibromas, 29 MPNST and two other cancers.
  • Biopsy confirmed the findings in 59 tumours and no MPNST was diagnosed on clinical follow-up of 23 lesions diagnosed as benign on FDG PET and PET CT.
  • CONCLUSION: FDG PET and PET CT is a sensitive and specific diagnostic tool for NF1-associated MPNST.


28. Upadhyaya M, Spurlock G, Monem B, Thomas N, Friedrich RE, Kluwe L, Mautner V: Germline and somatic NF1 gene mutations in plexiform neurofibromas. Hum Mutat; 2008 Aug;29(8):E103-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plexiform neurofibroma (PNF) is a congenital benign tumour present in 30-50% of NF1 patients, which in about 10-15% of cases, can develop into a malignant peripheral nerve sheath tumour (MPNST).
  • LOH of the NF1 gene region, as identified by marker analysis and/or MLPA, was detected in only 20/29 (69%) PNFs, compared to the >90% LOH previously found in MPNST.
  • [MeSH-minor] Adolescent. Adult. Child. DNA Mutational Analysis. Genes, p53. Humans. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Tumor Suppressor Protein p53 / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18484666.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Kinebuchi Y, Noguchi W, Igawa Y, Nishizawa O: Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol; 2005 Oct;10(5):353-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy.
  • The tumor was resected, and the pathological diagnosis was malignant peripheral nerve sheath tumor (MPNST).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nerve Sheath Neoplasms / drug therapy. Neurofibromatosis 1 / complications. Peripheral Nervous System Neoplasms / drug therapy. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Etoposide / administration & dosage. Humans. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247664.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


30. Wasa J, Nishida Y, Suzuki Y, Tsukushi S, Shido Y, Hosono K, Shimoyama Y, Nakamura S, Ishiguro N: Differential expression of angiogenic factors in peripheral nerve sheath tumors. Clin Exp Metastasis; 2008;25(7):819-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of angiogenic factors in peripheral nerve sheath tumors.
  • It is difficult to differentiate some malignant peripheral nerve sheath tumors (MPNST) from benign peripheral nerve sheath tumors (BPNST) histologically, and to predict the clinical outcome of patients with MPNST.
  • In this study, the expression of VEGF and MVD were evaluated immunohistochemically in 22 cases of MPNST, 14 of neurofibroma and 19 of schwannoma and correlation of the staining grade of VEGF or MVD and the various clinical factors were analyzed, and statistically evaluated.
  • Statistically higher positive staining for VEGF was observed in MPNST compared to neurofibroma (P=0.004) and schwannoma (P<0.001).
  • Even low grade MPNST showed higher VEGF positive staining than neurofibroma.
  • Moreover, high VEGF expression statistically correlated with the poor prognosis of the patients with MPNST (P=0.015).
  • Although MVD in MPNST was significantly higher than that in neurofibroma (P=0.038) and schwannoma (P<0.001), MVD could not predict the prognosis of the patients with MPNST.
  • Although VEGF mRNA expression tended to be higher in MPNST compared to neurofibroma, the difference was not significant.
  • Levels of VEGF protein expression serve as a novel diagnostic and prognostic tools for peripheral nerve sheath tumors.
  • [MeSH-major] Nerve Sheath Neoplasms / chemistry. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neurilemmoma / blood supply. Neurilemmoma / chemistry. Neurofibroma / blood supply. Neurofibroma / chemistry. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679811.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


31. Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H: Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest; 2007 Aug;87(8):767-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
  • Malignant peripheral nerve sheath tumor (MPNST) is rare, highly aggressive, resistant to radiochemotherapy, and associated with poor prognosis.
  • This study was designed to identify motogenic factor(s) involved in MPNST cell invasion and inhibitor(s) of such invasive activity.
  • We profiled the invasion-inducing activities of eight motogenic growth factors on two human MPNST cell lines, FU-SFT8611 and 9817, using in vitro Matrigel invasion assays.
  • Platelet-derived growth factor-BB (PDGF-BB) was identified as the most effective MPNST cell invasion-inducing factor.
  • Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) also stimulated invasion in one MPNST cell line.
  • Expressions of PDGF-BB and EGF receptors (PDGFR-beta and EGFR) mRNAs were detected more frequently and their proteins were expressed at higher levels in MPNST tissues than benign peripheral nerve sheath tumors (schwannomas and neurofibromas).
  • In both MPNST cell lines, PDGF-BB induced tyrosine phosphorylation of PDGFR-beta but not of PDGFR-alpha, and specific PDGFR-beta inhibition by small interfering RNA to the receptor inhibited PDGF-BB-stimulated MPNST cell invasion, suggesting the predominant role of PDGFR-beta.
  • No mutations were present in exons 12 and 18 of PDGFR-beta in both MPNST cell lines and 10 human MPNST tissues examined.
  • Our results indicated that PDGF-BB enhanced the invasive activity of MPNST cells through PDGFR phosphorylation and that imatinib inhibited such activity.
  • The results provide the ground for further assessment of the therapeutic potential of imatinib in suppressing the invasion and growth of MPNST.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Nerve Sheath Neoplasms / metabolism. Piperazines / pharmacology. Platelet-Derived Growth Factor / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Adult. Benzamides. Cell Line, Tumor. Female. Humans. Imatinib Mesylate. Intercellular Signaling Peptides and Proteins / pharmacology. Intercellular Signaling Peptides and Proteins / physiology. Male. Middle Aged. Mutation. Neoplasm Invasiveness. Phosphorylation. Proto-Oncogene Proteins c-sis. RNA, Messenger / metabolism. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / genetics. Receptor, Platelet-Derived Growth Factor beta / metabolism. Receptors, Growth Factor / genetics. Receptors, Growth Factor / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558420.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Intercellular Signaling Peptides and Proteins; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / Receptors, Growth Factor; 0 / platelet-derived growth factor BB; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


32. Matsumine A, Kusuzaki K, Nakamura T, Nakazora S, Niimi R, Matsubara T, Uchida K, Murata T, Kudawara I, Ueda T, Naka N, Araki N, Maeda M, Uchida A: Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol; 2009 Jul;135(7):891-900
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI.
  • PURPOSE: The imaging discrimination between neurofibroma (NF) and malignant peripheral nerve sheath tumor (MPNST) is clinically very important.
  • The purpose of this study is to define the criteria for the differential diagnosis between NF and MPNST on MRI in neurofibromatosis 1 (NF1).
  • RESULTS: The MRI findings characteristic of MPNST (p < 0.05) were an irregular tumor shape (15/19 in MPNST vs. 5/18 in NF), unclear margin (13/19 in MPNST vs. 6/18 in NF), intra-tumoral lobulation (12/19 in MPNST vs. 3/18 in NF), presence of high signal-intensity area on T1-weighted images (T1WI) (12/19 in MPNST vs. 1/18 in NF), no target sign (0/19 in MPNST vs. 12/18 in NF), inhomogeneous enhancement on contract-enhanced T1WI (17/18 in MPNST vs. 9/16 in NF) and a lower rate of enhanced area (54% in MPNST vs. 87% in NF) were critical indicators to differentiate MPNST from NF.
  • A multivariate analysis showed that intra-tumoral lobulation and the presence of a high signal-intensity area on T1WI were considered to be diagnostic indicators of MPNST.
  • CONCLUSION: MRI shows features which were helpful for differentiating MPNST from NF.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Nerve Sheath Neoplasms / diagnosis. Neurofibroma / diagnosis. Neurofibromatosis 1 / diagnosis. Peripheral Nervous System Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gadolinium. Humans. Male. Middle Aged. Radioisotopes. Tomography, Emission-Computed / methods. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101731.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radioisotopes; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


33. Santarius T, Chia HL, Xuereb JH, Kirollos RW: Sporadic malignant nerve sheath tumour of the oculomotor nerve. Acta Neurochir (Wien); 2007 Jun;149(6):617-22; discussion 622

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic malignant nerve sheath tumour of the oculomotor nerve.
  • Malignant peripheral nerve sheath tumours (MPNST) are exceedingly rare in an intracranial location.
  • In this report clinical and pathological evidence for the diagnosis of a MPNST arising from of the oclumotor nerve is presented.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Oculomotor Nerve Diseases / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Decompression, Surgical. Diagnosis, Differential. Diplopia / etiology. Female. Headache / etiology. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Microsurgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / diagnosis. Neoplasm, Residual / surgery. Ophthalmoplegia / etiology. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Radiosurgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17514351.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Zambrana F, Vicente F, García-Manrique T, Pereira S, Sáinz De Zaitigui J, De La Cruz Merino L: Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy. Clin Transl Oncol; 2010 Mar;12(3):231-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy.
  • Malignant peripheral nerve sheath tumours (MPNST) are a rare variety of soft tissue sarcomas (STS) arising from major peripheral nerve branches and typically located in the lower extremity, chest wall or the retroperitoneum.
  • It is a biologically aggressive neoplasm for which the treatment of choice is surgery, but usually requires a multimodality approach, having been generally labelled as chemoresistant.
  • We present a case of MPNST located intracranially with a good response to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Nerve Sheath Neoplasms / drug therapy
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231129.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


35. Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A: Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer; 2010 Jan 15;126(2):563-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
  • Neurofibromatosis type 1 (NF1) patients are prone to the development of malignant tumors, the most common being Malignant Peripheral Nerve Sheath Tumor (MPNST).
  • NF1-MPNST patients have an overall poor survival due to systemic metastasis.
  • Recently, the NF1 gene product, neurofibromin, was shown to negatively regulate the phosphoinositide-3-kinase (PI3K)/Protein Kinase-B (Akt)/mammalian Target Of Rapamycin (mTOR) pathway, with loss of neurofibromin expression in established human MPNST cell lines associated with high levels of mTOR activity.
  • We developed and characterized a human NF1-MPNST explant grown subcutaneously in NOD-SCID mice, to evaluate the effect of the mTOR inhibitor rapamycin.
  • We demonstrate that rapamycin significantly inhibited human NF1-MPNST mTOR pathway activation and explant growth in vivo at doses as low as 1.0 mg/kg/day, without systemic toxicities.
  • While rapamycin was effective at reducing NF1-MPNST proliferation and angiogenesis, with decreased CyclinD1 and VEGF respectively, there was no increase in tumor apoptosis.
  • [MeSH-major] Neurofibromatosis 1 / drug therapy. Peripheral Nervous System Neoplasms / drug therapy. Sirolimus / pharmacology. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Blotting, Western. Cyclin D1 / metabolism. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Humans. Immunohistochemistry. Male. Mice. Mice, Inbred NOD. Mice, SCID. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Ribosomal Protein S6 Kinases / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases. Tumor Burden / drug effects. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634141.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Vascular Endothelial Growth Factor A; 136601-57-5 / Cyclin D1; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


36. Holtkamp N, Atallah I, Okuducu AF, Mucha J, Hartmann C, Mautner VF, Friedrich RE, Mawrin C, von Deimling A: MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia; 2007 Aug;9(8):671-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
  • Malignant peripheral nerve sheath tumors (MPNST) are sarcomas with poor prognosis and limited treatment options.
  • Factors contributing to tumor progression are largely unknown.
  • We therefore examined MPNST from 22 neurofibromatosis type 1 (NF1) patients, 14 non-NF1 patients, and 14 neurofibroma patients for matrix metalloproteinase 13 (MMP-13) expression.
  • MMP-13 expression was detected in 58% of MPNST and was significantly associated with recurrent MPNST (P = .019).
  • p53 was observed in 78% of MPNST and was found to be strongly associated with MMP-13 expression (P = .005).
  • TP53 mutations were found in only 11% of MPNST and were associated with high tumor grades (P = .029).
  • No significant association between mutant TP53 and MMP-13 was observed, indicating that other factors drive MMP-13 expression in MPNST.
  • In summary, our data suggest that MMP-13 expression in nerve sheath tumors is coupled with malignant progression.
  • [MeSH-major] Biomarkers, Tumor / physiology. Genes, p53 / physiology. Matrix Metalloproteinase 13 / physiology. Nerve Sheath Neoplasms / metabolism. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Middle Aged. Mutation. Neurofibroma / genetics. Neurofibroma / metabolism. Neurofibroma / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • [Cites] J Cell Sci. 2000 Jan;113 Pt 2:227-35 [10633074.001]
  • [Cites] Clin Chim Acta. 2000 Feb 15;291(2):137-55 [10675720.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):883-7 [10706099.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11327-32 [10753945.001]
  • [Cites] Gut. 2000 Jul;47(1):50-6 [10861264.001]
  • [Cites] Hum Mutat. 2000 Aug;16(2):181 [10923052.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):202-6 [11135438.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):733-43 [10360651.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):213-24 [15816541.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1602-11 [16550160.001]
  • [Cites] Lab Invest. 2001 Jun;81(6):833-44 [11406645.001]
  • [Cites] J Clin Pathol. 2001 Aug;54(8):631-6 [11477120.001]
  • [Cites] Int J Cancer. 2002 Jan 20;97(3):283-9 [11774278.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1187-95 [11850838.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):269-72 [11927843.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):610-5 [12070601.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):578-84; discussion 602-4, 646-51 [12403556.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Acta Neuropathol. 2004 Feb;107(2):159-68 [14673600.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5111-23 [15094779.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1544-50 [8576151.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):761-8 [8609233.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):1-6 [8821948.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Arch Pathol Lab Med. 1997 Apr;121(4):395-9 [9140310.001]
  • [Cites] J Invest Dermatol. 1997 Aug;109(2):225-31 [9242512.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):405-8 [9537326.001]
  • [Cites] Nature. 1998 May 21;393(6682):229-34 [9607760.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1092-100 [9891044.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):469-80 [10027405.001]
  • [Cites] APMIS. 1999 Jan;107(1):45-53 [10190279.001]
  • [Cites] Biochem J. 1999 May 15;340 ( Pt 1):171-81 [10229672.001]
  • (PMID = 17786186.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.- / Matrix Metalloproteinase 13
  • [Other-IDs] NLM/ PMC1950437
  • [Keywords] NOTNLM ; Malignant peripheral nerve sheath tumor / TP53 / malignant progression / matrix metalloproteinase 13 / neurofibromatosis type 1
  •  go-up   go-down


37. Radha S, Afroz T, Satyanarayana G: Paratesticular malignant peripheral nerve sheath tumour: a case report. Indian J Pathol Microbiol; 2006 Oct;49(4):614-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular malignant peripheral nerve sheath tumour: a case report.
  • Primary malignant peripheral nerve sheath tumours (MPNST) of intrascrotal extra testicular site are extremely rare with only few cases reported in literature.
  • These are highly malignant tumours most often associated with neurofibromatosis.
  • The lesion was excised and was diagnosed as MPNST.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Sarcoma / diagnosis. Scrotum / pathology
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183877.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


38. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC: Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer; 2010 Jan 15;116(2):451-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
  • BACKGROUND: Correct pretreatment classification is critical for optimizing diagnosis and treatment of patients with peripheral nerve sheath tumors (PNSTs).
  • The aim of this study was to evaluate whether F18-fluorodeoxyglucose positron emission tomography (FDG PET) can differentiate malignant (MPNST) from benign PNSTs.
  • METHODS: Thirty-four adult patients presenting with PNST who underwent a presurgical FDG PET/computed tomography (CT) scan between February 2005 and November 2008 were included in the study.
  • Tumors were characterized histologically, by FDG maximum standardized uptake value (SUV(max) [g/mL]), and by CT size (tumor maximal diameter [cm]).
  • The accuracy of FDG PET for differentiating MPNSTs from benign PNSTs (neurofibroma and schwannoma) was evaluated by receiver operating characteristic (ROC) curve analysis.
  • SUV(max) was significantly higher in MPNST compared with benign PNST (12.0 +/- 7.1 vs 3.4 +/- 1.8; P < .001).
  • By ROC curve analysis, SUV(max) reliably differentiated between benign and malignant PNSTs (area under the ROC curve of 0.97).
  • Given the difficulties in clinically evaluating PNST and in distinguishing benign PNST from MPNST, FDG PET imaging should be used for diagnostic intervention planning and for optimizing treatment strategies.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 2001 Oct;28(10):1541-51 [11685498.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2856-63 [19351756.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):542-6 [11914894.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):29-43 [12533638.001]
  • [Cites] Eur J Surg Oncol. 2003 Aug;29(6):536-41 [12875862.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:25S-35S [14736833.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):971-4 [15039173.001]
  • [Cites] J Nucl Med. 2004 May;45(5):797-801 [15136629.001]
  • [Cites] Lab Invest. 1983 Sep;49(3):299-308 [6310227.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Ann Surg Oncol. 1995 Mar;2(2):126-31 [7728565.001]
  • [Cites] Med Phys. 1998 Oct;25(10):2046-53 [9800714.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2270-5 [15484214.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):603-7 [15809482.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):15-22 [16311108.001]
  • [Cites] Nat Med. 2006 Jan;12(1):122-7 [16341243.001]
  • [Cites] Virchows Arch. 2006 Dec;449(6):673-81 [17103226.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):928-35 [17885067.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):390-4 [17932395.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7 [10675220.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1509-17 [11083540.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1336-40 [11585292.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):715-20 [18245531.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):340-9 [18286466.001]
  • [Cites] J Nucl Med. 2008 Jul;49(7):1038-46 [18552153.001]
  • [Cites] Oral Dis. 2008 Sep;14(6):510-3 [18826382.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 May;36(5):751-7 [19142634.001]
  • [ErratumIn] Cancer. 2010 Feb 1;116(3):775
  • (PMID = 19924789.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA086306; United States / NCI NIH HHS / CA / 5 P50 CA086306
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS324300; NLM/ PMC3188986
  •  go-up   go-down


39. Karatzoglou P, Karagiannidis A, Kountouras J, Christofiridis CV, Karavalaki M, Zavos C, Gavalas E, Patsiaoura K, Vougiouklis N: Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature. Anticancer Res; 2008 Sep-Oct;28(5B):3107-13
MedlinePlus Health Information. consumer health - Constipation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature.
  • A malignant peripheral nerve sheath tumor (MPNST) is a rare neoplasm arising from peripheral nerve sheaths.
  • We herein report the first case of MPNST originating from the left gluteal muscle region, diffusely extending into the adjacent small pelvis and perineum.
  • A computed tomography scan revealed a giant tumor which displaced the bladder and segments of the intestine.
  • The histopathological diagnosis was MPNST.
  • [MeSH-major] Constipation / etiology. Nerve Sheath Neoplasms / complications. Neurofibromatosis 1 / complications. Urinary Retention / etiology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031965.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


40. Rawal A, Yin Q, Roebuck M, Sinopidis C, Kalogrianitis S, Helliwell TR, Frostick S: Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature. Microsurgery; 2006;26(2):80-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature.
  • Tumor involvement of the brachial plexus is uncommon.
  • Malignant peripheral nerve-sheath tumors (MPNST) are rare at this site, arising spontaneously or in the context of NF-1.
  • MPNST are intermediate or high-grade sarcomas with a high risk of local and distant spread.
  • Approximately 50% of MPNST arise in patients with NF-1, and therefore these patients should be thoroughly investigated for any new symptoms or masses.
  • MPNST of the brachial plexus should be treated with an adequate wide local excision, with adjuvant high-dose radiotherapy pre- or postoperatively.
  • The role of chemotherapy in the treatment of MPNST is not clearly defined, but it may have some benefit in salvaging treatment failures.
  • [MeSH-major] Brachial Plexus. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Neurofibromatosis 1 / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538633.001).
  • [ISSN] 0738-1085
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


41. Shimizu K, Okita R, Uchida Y, Hihara J: Long survival after resection for lung metastasis of malignant peripheral nerve sheath tumor in neurofibromatosis 1. Ann Thorac Cardiovasc Surg; 2008 Oct;14(5):322-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long survival after resection for lung metastasis of malignant peripheral nerve sheath tumor in neurofibromatosis 1.
  • A 31-year-old man with neurofibromatosis 1 (NF1) was admitted for the treatment of solitary lung tumor.
  • Nine months earlier he had undergone a large resection for malignant peripheral nerve sheath tumors (MPNSTs) in his back.
  • Surgical resection of the right lower lobe was performed, and the tumor was pathologically diagnosed as a metastasis of MPNST.
  • The survival of patients with pulmonary metastasis of MPNST is extremely poor, especially of those with NF1, but this patient has survived 5 years without recurrence.
  • [MeSH-major] Lung Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Neurofibromatosis 1 / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Humans. Male. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989250.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Friedrich RE, Derlin T, Hagel C: Atypical plexiform neurofibroma in NF1 with high standardised uptake value (SUV) in positron-emission tomography (PET) expressing podoplanin. In Vivo; 2010 Nov-Dec;24(6):871-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 19-year-old female with established neurofibromatosis type 1 (NF1) diagnosis and history of malignant peripheral nerve sheath tumour (MPNST) of the lower extremities showed a tumour of her right upper extremity with a maximum standardised uptake value (SUV) of 5.7 on positron emission/computerised tomography (PET/CT) scan.
  • Scattered nerve fibres were labelled with neurofilament antibodies within the tumour.
  • This atypical neurofibroma showed a high SUV on PET that is indicative for MPNST.
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Female. Humans. Positron-Emission Tomography. Young Adult

  • Genetic Alliance. consumer health - Neurofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21164047.001).
  • [ISSN] 1791-7549
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  •  go-up   go-down


43. Pfeiffer J, Arapakis I, Boedeker CC, Ridder GJ: Malignant peripheral nerve sheath tumour of the paranasal sinuses and the anterior skull base. J Craniomaxillofac Surg; 2008 Jul;36(5):293-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumour of the paranasal sinuses and the anterior skull base.
  • BACKGROUND: Malignant peripheral nerve sheath tumours (MPNSTs) are highly aggressive neoplasms with a marked propensity for local recurrence and metastatic spread.
  • PATIENTS AND METHODS: We present a case of MPNST of the anterior skull base and provide an overview of all MPNSTs reported since 1970, in which the tumour location was the anterior skull base or the paranasal sinuses.
  • CONCLUSIONS: Despite multimodal therapy and advances in surgical techniques, the prognosis of MPNST located in the paranasal sinuses and the anterior skull base remains dismal.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Prognosis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362076.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 38
  •  go-up   go-down


44. del Carmen Baena-Ocampo L, Reyes-Sánchez A, Alpízar-Aguirre A, Rosales-Olivares LM: Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: report of two clinical cases. Cir Cir; 2009 Sep-Oct;77(5):391-5
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: report of two clinical cases.
  • BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is a sarcoma with a high grade of malignancy originating in the nerve sheath components, fibroblasts, perineural cells, and Schwann cells.
  • CLINICAL CASES: We present two cases of NF-1-associated MPNST.
  • Histologically, it corresponded to a neurofibromatosis lesion in transition with malignant neoplasm.
  • Associated with the deformity, MRI showed a withering tumor in the posterior thoracic region (T1-T8), observing an infiltrating, cellular sarcomatous neoplasm with immunopositivity for S-100 protein and vimentin.
  • Due to the progressive growth of MPNST and the anatomic difficulty for its approach, there should be strict surveillance of patients with NF-1 for early detection of malignant transformation in these lesions.
  • [MeSH-major] Cervical Vertebrae. Nerve Sheath Neoplasms / genetics. Neurofibromatosis 1 / pathology. Spinal Neoplasms / genetics. Thoracic Vertebrae
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Humans. Kyphosis / etiology. Laminectomy. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / radiotherapy. Nerve Compression Syndromes / etiology. S100 Proteins / analysis. Scoliosis / etiology. Spinal Nerve Roots. Vimentin / analysis. Young Adult


45. Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A: Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery; 2009 Oct;65(4 Suppl):A160-70
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
  • OBJECTIVE: Benign plexiform neurofibromas (PNfib), especially those occurring in patients with neurofibromatosis type 1, are at a significant risk of progressing to a malignant peripheral nerve sheath tumor (MPNST).
  • Early diagnosis, followed by radical surgery and adjuvant radiation to maintain local tumor control, is of critical importance to prevent metastasis and subsequent mortality from MPNSTs.
  • However, early diagnosis is hampered by the sensitivity of current imaging modalities such as computed tomography (CT) or magnetic resonance imaging to reliably detect this malignant transformation, which can occur heterogeneously in a PNfib to a MPNST.
  • METHODS: In this prospective study, 9 neurofibromatosis type 1-associated PNfibs suspected to have undergone transformation to an MPNST were preoperatively evaluated by 18FDG-PET/CT and magnetic resonance imaging.
  • A detailed histological evaluation correlated the average and regional standard uptake value (SUV) from the 18FDG-PET/CT to grade of malignancy of the suspected MPNST.
  • Stratification of the maximal SUV to low (<4.0), intermediate (4.0-7.0), or high (>7.0) correlated to the proliferative index (Ki-67) and grade of MPNST.
  • A maximal SUV of more than 7.0 was closely correlated to a focus of malignant transformation.
  • [MeSH-major] Nerve Sheath Neoplasms / radionuclide imaging. Neurofibroma / radionuclide imaging. Neurofibromatosis 1 / radionuclide imaging. Peripheral Nerves / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Tomography, X-Ray Computed. Young Adult


46. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Iwamoto Y, Tsuneyoshi M: Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol; 2006 Apr;19(4):524-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CHFR in malignant peripheral nerve sheath tumors.
  • In MPNST, complex karyotypes showing numerical and structural aberrations have been described.
  • We examined the expression of CHFR in 96 cases of MPNST by immunohistochemical and molecular methods.
  • We found reduced (score, < or = 3) expression of CHFR in 63 out of 96 (66%) cases of MPNST, and such alteration was significantly correlated with a high mitotic count, a high Ki-67-labeling index, and a poor prognosis.
  • In addition, MPNST with normal karyotype showed a strong (score, =5) expression of CHFR.
  • Our results support the assertion that CHFR functions as an inhibitor of tumor proliferation.
  • [MeSH-major] Cell Cycle Proteins / genetics. Neoplasm Proteins / genetics. Nerve Sheath Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / analysis. Male. Middle Aged. Multivariate Analysis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554732.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


47. Bensaid B, Giammarile F, Mognetti T, Galoisy-Guibal L, Pinson S, Drouet A, Combemale P: [Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1]. Ann Dermatol Venereol; 2007 Oct;134(10 Pt 1):735-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appearance of malignant peripheral nerve sheath tumours (MPNST) marks a critical stage in the course of neurofibromatosis type 1 (NF1).
  • We assessed the value of 18 FDG positron emission tomoscintigraphy (PET scan) in screening for such malignant tumours.
  • PATIENTS AND METHODS: Between October 2000 and August 2006, all of our patients with NF1 and suspected MPNST underwent PET scan.
  • In 8 patients, PET scan showed suspect lesions (12 tumours), and histological analysis of these tumours revealed 6 MPNST.
  • In 30 patients (37 tumours) PET scan showed non-suspect binding, and no malignant tumours were demonstrated either on histological examination or after mean follow-up of 33.5 months.
  • DISCUSSION: Our study, to our knowledge the most extensive yet performed, demonstrates the value of PET scan in detecting MPNST, particularly based on its 100% negative predictive value.
  • The first involved 18 NF1 patients with 23 plexiform neurofibromas: of 7 tumours with hyperbinding, 5 were MPNST.
  • The second study concerned 5 NF1 patients with a total of 15 tumours: 7 tumours showed hyperbinding, of which 6 were MPNST.
  • [MeSH-major] Fluorodeoxyglucose F18. Neurofibromatosis 1 / complications. Positron-Emission Tomography. Radiopharmaceuticals. Sarcoma / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Decision Trees. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978710.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


48. Verdijk RM, den Bakker MA, Dubbink HJ, Hop WC, Dinjens WN, Kros JM: TP53 mutation analysis of malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol; 2010 Jan;69(1):16-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutation analysis of malignant peripheral nerve sheath tumors.
  • Mutations in TP53 underlie the development of malignant peripheral nerve sheath tumors (MPNSTs) in animal models, but there is controversy regarding the extent of TP53 mutations in human MPNSTs.
  • A minority of patients (n = 26, 30%) had neurofibromatosis type 1 (NF1); in these patients, the diagnosis of MPNST was made at younger ages (33 [SD, 3.6] years vs 49 [SD, 2.9] years in NF1 vs non-NF1; p = 0.003).
  • These results indicate that TP53 mutations are relatively rare in human MPNST and that they are not positively correlated with the presence of NF1.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Mutation / genetics. Nerve Sheath Neoplasms / genetics. Peripheral Nervous System Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Child. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Neurofibromatosis 1 / genetics. Retrospective Studies. Statistics, Nonparametric. Ubiquitin-Protein Ligases / metabolism. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010306.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


49. Hara M, Matsuzaki Y, Shimizu T, Tomita M, Ayabe T, Enomoto Y, Wada S, Tanaka H, Kataoka H, Nabeshima K, Onitsuka T: Malignant peripheral nerve sheath tumor with Horner's syndrome: a case report. Ann Thorac Cardiovasc Surg; 2008 Aug;14(4):246-8
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor with Horner's syndrome: a case report.
  • We report on a 42-year-old woman with malignant peripheral nerve sheath tumor (MPNST) arising from the cervical sympathetic nerve.
  • The mass was spindle shaped and connected to the sympathetic trunk on the cranial and caudal sides, and it compressed the left carotid sheath on the median side.
  • [MeSH-major] Horner Syndrome / complications. Peripheral Nervous System Neoplasms / pathology. Sympathetic Nervous System / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Sternum / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Horner's syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818575.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


50. Hemalatha AL, Karthikeyan TM, Bharatnur SS, Kumar AS: Malignant peripheral nerve sheath tumor in oral cavity--a rare site. Indian J Pathol Microbiol; 2006 Jul;49(3):397-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor in oral cavity--a rare site.
  • MPNST occurring in oral cavity, which is a rare site for the tumour, in a 35 year old female patient with history of swelling underneath the tongue present since one year diagnosed clinically as ranula is presented here.
  • Histopathological examination of the excised mass showed features of spindle cell sarcoma following which a provisional diagnosis of MPNST was offered.
  • [MeSH-major] Mouth / pathology. Mouth Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001897.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


51. Albayrak BS, Gorgulu A, Kose T: A case of intra-dural malignant peripheral nerve sheath tumor in thoracic spine associated with neurofibromatosis type 1. J Neurooncol; 2006 Jun;78(2):187-90
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intra-dural malignant peripheral nerve sheath tumor in thoracic spine associated with neurofibromatosis type 1.
  • Histopathological diagnosis was malignant peripheral nerve sheath tumor (MPNST), a rare sarcoma with a dismal prognosis.
  • Tumor recurred in its previous site with an adjacent apical mass in the left lung 7 weeks following initial surgery and repeat surgery was performed with complete removal of intra-dural tumor.
  • We report the first patient with intra-dural MPNST localized proximal to conus medullaris; in upper thoracic spine.
  • It must always be considered the possibility of a rare but a devastating tumor, MPNST beside schwannomas and neurofibromas in patients with NF1 when an intra-spinal mass is diagnosed.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Dura Mater / pathology. Humans. Male. Neoplasm Recurrence, Local / surgery. Thoracic Vertebrae. Treatment Outcome


52. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A: Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer; 2006 Sep 1;107(5):1065-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution.
  • BACKGROUND: The authors explored the prognostic factors and clinical outcomes of patients who had malignant peripheral nerve sheath tumors (MPNST) with and without neurofibromatosis type 1 (NF-1).
  • METHODS: Two hundred five patients with localized MPNST who underwent surgery at the Istituto Nazionale per lo Studio e la Cura dei Tumori (Milan, Italy) over 25 years were reviewed.
  • Presentation with either primary or recurrent disease, tumor size, and tumor site (trunk vs. extremity) were the strongest independent predictors of survival.
  • The results confirmed that patients with MPNST share similar prognostic factors with patients who have other soft tissue sarcomas and have some of the worst clinical outcomes.
  • [MeSH-major] Nerve Sheath Neoplasms / mortality. Neurofibromatosis 1 / complications
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16881077.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Silvestre DC, Gil GA, Tomasini N, Bussolino DF, Caputto BL: Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice. PLoS One; 2010;5(3):e9544
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice.
  • PRINCIPAL FINDINGS: In human samples, c-Fos expression was at the limit of detection in non-pathological specimens, but was abundantly expressed associated to ER membranes in tumor cells.
  • This was also observed in CNS of adult tumor-bearing NPcis mice but not in NPcis fos(-/-) KO mice.
  • A glioblastoma multiforme and a malignant PNS tumor from a NF1 patient (MPNST) showed a 2- and 4- fold c-Fos-dependent phospholipid synthesis activation, respectively.
  • MPNST samples also showed increased cell proliferation rates and abundant c-Fos expression.
  • They also disclose this protein as a potential target for controlling tumor growth in the nervous system.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] J Neurosci Res. 2009 Aug 1;87(10):2273-81 [19267420.001]
  • [Cites] Neurochem Res. 2000 Jan;25(1):153-62 [10685615.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Genes Dev. 2000 Nov 1;14(21):2695-700 [11069886.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 12;280(1):9-13 [11162469.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] FASEB J. 2001 Mar;15(3):556-8 [11259365.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4369-78 [11390664.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Apr 30;135(1-2):71-7 [11978395.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Trends Mol Med. 2003 Jan;9(1):19-23 [12524206.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1881-94 [14767061.001]
  • [Cites] Glia. 1989;2(4):223-30 [2527821.001]
  • [Cites] Nature. 1989 Aug 17;340(6234):568-71 [2505081.001]
  • [Cites] J Neurochem. 1990 Dec;55(6):1855-60 [2230799.001]
  • [Cites] Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57 [1751545.001]
  • [Cites] Neuron. 1992 Jan;8(1):13-23 [1730004.001]
  • [Cites] Cell. 1992 Nov 13;71(4):577-86 [1423615.001]
  • [Cites] Nature. 1992 Dec 24-31;360(6406):741-5 [1465144.001]
  • [Cites] Trends Neurosci. 1995 Feb;18(2):66-7 [7537412.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] J Neurosci Res. 1996 Jan 1;43(1):93-8 [8838579.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):10-5 [9685570.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):1228-35 [10461916.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Aug 1;214(3):263-9 [16473383.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3551-8 [17160021.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10631-4 [18006802.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):31163-71 [18784083.001]
  • [Cites] J Neurosci Res. 2009 Mar;87(4):857-65 [18951474.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 20209053.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-fos
  • [Other-IDs] NLM/ PMC2832012
  •  go-up   go-down


54. Schittenhelm J, Thiericke J, Nagel C, Meyermann R, Beschorner R: WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy. Cancer Biomark; 2010;7(2):73-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy.
  • OBJECTIVE: Wilms' tumor protein (WT1) expression is usually absent in normal glial cells of the CNS but is highly upregulated in brain tumor cells and its expression correlates with tumor grade.
  • However, knowledge on WT1 expression in tumors of the peripheral nerve system (PNS) is limited.
  • As WT1 antibodies not only serve as biomarker for cancerous tissue but also are considered for cancer immunotherapy, knowledge of WT1 expression in tumorous and normal peripheral nerve tissue is important for therapeutical purposes.
  • METHODS: We analyze the immunohistochemical expression of WT1 in 101 samples consisting of 13 normal nerves, 10 neurofibromas, 69 schwannomas and 9 malignant peripheral nerve sheath tumors (MPNST).
  • Tumor samples included 14 specimen from patients with a proven neurocutaneous disorder (neurofibromatosis type 1 and 2) and 3 cases of schwannomatosis.
  • In 50 vestibular schwannomas tumor growth extension was correlated to WT1 expression.
  • In peripheral nerve sheath tumors, cytoplasmic WT1 protein is expressed in the cytoplasm of the neoplastic cells in all tumors, including MPNST, neurofibromas and schwannomas.
  • The WT1 expression is independent of tumor malignancy or tumor growth extension and is not associated with a neurocutaneous disorder.
  • CONCLUSION: WT1 expression in normal and neoplastic tissue differs in the peripheral and the central nervous system.
  • [MeSH-major] Cranial Nerve Neoplasms / metabolism. Cranial Nerves / metabolism. Nerve Sheath Neoplasms / metabolism. Peripheral Nerves / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Child. Female. Humans. Male. Middle Aged. Neurilemmoma / metabolism. Neurofibroma / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21178265.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


55. Widemann BC: Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep; 2009 Jul;11(4):322-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1).
  • The response rate of MPNSTs to standard chemotherapeutic agents used to treat pediatric and adult soft tissue sarcomas is unknown and is currently undergoing evaluation in a multi-institutional clinical trial.
  • This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy.
  • [MeSH-major] Nerve Sheath Neoplasms / genetics. Nerve Sheath Neoplasms / therapy. Neurofibromatosis 1 / complications
  • [MeSH-minor] Clinical Trials as Topic. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Genome-Wide Association Study. Nuclear Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics. Vascular Endothelial Growth Factor A / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508838.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / tumor suppressor protein p73; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 80
  •  go-up   go-down


56. Di Giovannantonio L, Bellocci R, Zappacosta R, Zappacosta B, Castrataro A, Liberatore M, Liberati M, Angelucci D: [Primary malignant schwannoma of the uterine cervix: a malignant tumor with unusual behaviour. A case report]. Pathologica; 2005 Feb;97(1):7-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant schwannoma of the uterine cervix: a malignant tumor with unusual behaviour. A case report].
  • [Transliterated title] Schwannoma maligno primitivo della cervice uterina: un tumore maligno a comportamento inusuale. Caso clinico.
  • Malignant tumors of peripheral nerves (MPNST) represent approximately 5-10% of all soft tissue sarcomas and usually are in relationship with a major nerve.
  • Primary cervical malignant Schwannomas are very rare neural sheat tumors that, grossly and clinically, are misdiagnosed for other more frequent lesions of the uterine cervix.
  • We report a case of primary cervical malignant Schwannoma in a 27 years old female with atypical bleeding.
  • [MeSH-major] Neurilemmoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathologica. 2005 Jun;97(3):159. Zappacosta, B [added]
  • (PMID = 15918410.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 9
  •  go-up   go-down


57. Prayson RA, Yoder BJ, Barnett GH: Epidermal growth factor receptor is not amplified in schwannomas. Ann Diagn Pathol; 2007 Oct;11(5):326-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both neurofibromas and schwannomas are capable of progression to malignant peripheral nerve sheath tumors (MPNSTs).
  • The mitogenic signaling for schwannomas is unlikely to be related to overexpression or amplification of EGFR; however, acquiring this signaling pathway might contribute to the progression of a subset of benign peripheral nerve sheath tumors to MPNST.
  • [MeSH-major] Nerve Sheath Neoplasms / metabolism. Neurilemmoma / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. DNA, Neoplasm / genetics. Disease Progression. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17870017.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


58. Merimsky O, Soyfer V, Kovner F, Bickels J, Issakov J, Flusser G, Meller I, Ofer O, Kollender Y: Limb sparing approach: adjuvant radiation therapy in adults with intermediate or high-grade limb soft tissue sarcoma. Radiother Oncol; 2005 Dec;77(3):295-300
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb sparing approach: adjuvant radiation therapy in adults with intermediate or high-grade limb soft tissue sarcoma.
  • PATIENTS AND METHODS: Between October 1994 and October 2002, 133 adult patients with intermediate or high-grade limb STS were approached by LSS+RT.
  • DFS and OS were influenced by disease stage II vs I, primary site in the upper limb vs lower limb, MPNST vs other types, induction therapy vs no induction, adequate resection vs marginal resection or involved margins, and good response to induction therapy vs bad response.
  • DFS and OS were Patient's age and sex, tumor depth, acute or late toxicity of RT, or the interval of time between the date of definitive surgery and the start of RT did not affect DFS and or OS.
  • [MeSH-major] Limb Salvage. Sarcoma / radiotherapy. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Radiotherapy, Conformal. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300847.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


59. Shah H, Pervez S: Immunophenotypic characterization of high grade pleomorphic sarcomas: a demographic and immunohistochemical study in a major referral center of Pakistan. J Pak Med Assoc; 2005 Mar;55(3):101-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 134 cases which were characterized, 38.1% were pleomorphic leiomyosarcoma, followed by pleomorphic rhabdomyosarcoma 14.9%, Malignant Peripheral Nerve Sheath Tumour 9%, pleomorphic liposarcoma 3.7% and pleomorphic storiform Malignant Fibrous Histiocytoma 0.7%.
  • Mean/ median age for Leiomyosarcoma was 50/50, for Rhabdomyosarcomas 33/22, for MPNST 42/41, for Liposarcoma 52/50 and for Malignant Fibrous Histiocytoma 46/46 respectively.
  • CONCLUSION: It was concluded that the most common pleomorphic sarcoma occurring in our adult population was Leiomyosarcoma, and that immunohistochemical stains are essential in most cases for further characterization of pleomorphic high grade sarcoma.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Antigens, Neoplasm / immunology. Biomarkers, Tumor / analysis. Cross-Sectional Studies. Humans. Immunoenzyme Techniques. Immunohistochemistry. Leiomyosarcoma / pathology. Liposarcoma / genetics. Liposarcoma / pathology. Middle Aged. Nerve Sheath Neoplasms / genetics. Nerve Sheath Neoplasms / pathology. Pakistan. Phenotype. Rhabdomyosarcoma / genetics. Rhabdomyosarcoma / pathology. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852744.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Siqueira MG, Martins RS, Teixeira MJ: Management of brachial plexus region tumours and tumour-like conditions: relevant diagnostic and surgical features in a consecutive series of eighteen patients. Acta Neurochir (Wien); 2009 Sep;151(9):1089-98
MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FINDINGS: The tumours comprised a heterogeneous group of lesions, including schwannomas, neurofibromas, malignant peripheral nerve sheath tumour (MPNST), sarcomas, metastases, desmoids and an aneurysmal bone cyst.
  • Eleven tumours were benign and 7 were malignant.
  • Some of the malignant tumours could be controlled by surgery plus adjuvant therapy, but this category is still associated with high morbidity and mortality rates.
  • [MeSH-major] Brachial Plexus / pathology. Brachial Plexus / surgery. Brachial Plexus Neuropathies / diagnosis. Brachial Plexus Neuropathies / surgery. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Bone Cysts, Aneurysmal / diagnosis. Bone Cysts, Aneurysmal / pathology. Bone Cysts, Aneurysmal / surgery. Child. Female. Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / physiopathology. Fibromatosis, Aggressive / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / physiopathology. Neoplasm Recurrence, Local / epidemiology. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / physiopathology. Nerve Sheath Neoplasms / surgery. Neurilemmoma / diagnosis. Neurilemmoma / physiopathology. Neurilemmoma / surgery. Neurofibroma / diagnosis. Neurofibroma / physiopathology. Neurofibroma / surgery. Neurosurgical Procedures. Pain / etiology. Paresthesia / etiology. Postoperative Complications / epidemiology. Retrospective Studies. Sarcoma / diagnosis. Sarcoma / physiopathology. Sarcoma / surgery. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448970.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


61. Wimmer K: [Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome]. Wien Med Wochenschr; 2005 Jun;155(11-12):273-80
Genetic Alliance. consumer health - TUMOR PREDISPOSITION SYNDROME.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome].
  • [Transliterated title] Neurofibromatose: die häufigste Tumor-disponierende genetische Erkrankung.
  • However, the disorder should not be underestimated as a "mere cosmetic problem", since NF1 patients are at increased risk to also develop malignant tumours, such as malignant peripheral nerve sheath tumours (MPNST), juvenile myelomonocytic leukaemia (JMML), optic glioma and pheochomocytoma.
  • [MeSH-minor] Adolescent. Adult. Child. Chromosome Aberrations. DNA Mutational Analysis. Disease Susceptibility. Genetic Counseling. Genetic Predisposition to Disease / genetics. Genetic Testing. Genotype. Heterozygote Detection. Humans. Neurofibromin 1 / genetics. Neurofibromin 2 / genetics. Phenotype. Risk

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035388.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Neurofibromin 2
  •  go-up   go-down


62. Ziadi A, Saliba I: Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review. Auris Nasus Larynx; 2010 Oct;37(5):539-45
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.
  • OBJECTIVES: The incidence of malignant peripheral nerve sheath tumor (MPNST) is approximately 0.001%.
  • (1) to review all cases of intracranial MPNST described in the literature, (2) to highlight the suspicion of intracranial MPNST, (3) to identify the gross pathology, the histopathology, the immunohistochemistry, (4) to discuss the differential diagnosis, the treatment, the recurrence rate, the follow-up, the incidence of metastasis and the prognosis.
  • We used the following Keywords: "malignant peripheral nerve sheath tumor", "cranial nerve", "neurosarcoma", "malignant schwannoma", "neurofibroma", "malignant neurofibroma" and "nerve tumor".
  • We considered cases where MPNST involved an intracranial cranial nerve.
  • RESULTS: We identified 32 cases of cranial MPNST including our case.
  • Most cases are developed sporadically (50%), 31% arise from a malignant transformation of schwannoma and 19% from a neurofibroma.
  • The cranial nerve VIII is the most involved (15/32), followed by the Vth (10/32) and the VIIth (5/32).
  • MPNST will strongly express protein S-100 and collagen IV-laminin.
  • 13 cases were treated with radiotherapy for tumor recurrence and metastasis.
  • CONCLUSION: MPNST of cranial nerves are very rare.
  • In neurofibroma, even though MPNST is mainly associated to type 1, we should keep in mind its association to NF2.
  • Inaccessibility of cranial MPNST may explain the subtotal resection and thus the poor prognosis.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic / pathology. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neurilemmoma / diagnosis. Neurilemmoma / pathology. Neurilemmoma / radiotherapy. Neurilemmoma / surgery. Neurofibroma / diagnosis. Neurofibroma / pathology. Neurofibroma / radiotherapy. Neurofibroma / surgery. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / pathology. Neurofibromatosis 1 / radiotherapy. Neurofibromatosis 1 / surgery. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / pathology. Neurofibromatosis 2 / radiotherapy. Neurofibromatosis 2 / surgery. Radiotherapy, Adjuvant. Spinal Neoplasms / mortality. Spinal Neoplasms / pathology. Spinal Neoplasms / secondary. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399579.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


63. Rekhi B, Ingle A, Kumar R, DeSouza MA, Dikshit R, Jambhekar NA: Malignant peripheral nerve sheath tumors: clinicopathological profile of 63 cases diagnosed at a tertiary cancer referral center in Mumbai, India. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):611-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors: clinicopathological profile of 63 cases diagnosed at a tertiary cancer referral center in Mumbai, India.
  • BACKGROUND: A malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma, characterized by an aggressive course and forms a diagnostic challenge, in view of its varied histomorphology.
  • Average tumor (T) size was 9.9 cm, with 72.9% cases having T size > 5 cm.
  • CONCLUSIONS: A MPNST has multifaceted histomorphology.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Female. Histocytochemistry. Humans. India. Male. Microscopy. Middle Aged. Recurrence. Severity of Illness Index. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045379.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


64. Agaram NP, Prakash S, Antonescu CR: Deep-seated plexiform schwannoma: a pathologic study of 16 cases and comparative analysis with the superficial variety. Am J Surg Pathol; 2005 Aug;29(8):1042-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deep-seated plexiform schwannoma: a pathologic study of 16 cases and comparative analysis with the superficial variety.
  • Plexiform schwannoma (PS) is one of the least common histologic variants of schwannoma.
  • However, the frequent cellular morphology associated with hyperchromatic nuclei, increased mitoses, and plexiform growth can suggest a malignant process, mainly a high-grade malignant peripheral nerve sheath tumor (MPNST).
  • Fifteen tumors were located in the deep somatic soft tissue (extremities, 8; retroperitoneum/pelvis, 3; trunk, 2; parotid, 1; vulva, 1) and 1 tumor was located in the thoracic esophagus.
  • The 8 superficial PSs showed increased cellularity and mild to moderate pleomorphism in 62% of cases but lacked tumor necrosis.
  • [MeSH-major] Neurilemmoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006798.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


65. Zhang J, Sun Y, Peng ZL: Malignant peripheral nerve sheath tumor of the vagina. Saudi Med J; 2009 May;30(5):705-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the vagina.
  • Malignant peripheral nerve sheath tumors (MPNSTs) usually develop in major nerve trunks, giving rise to tumors in the proximal portions of the upper and lower extremities and trunk.
  • We describe a case of MPNST of the vagina and discuss its diagnosis and treatment.
  • [MeSH-major] Peripheral Nerves / pathology. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417975.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


66. Minovi A, Basten O, Hunter B, Draf W, Bockmühl U: Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck; 2007 May;29(5):439-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review.
  • BACKGROUND: This study analyzes the management and outcomes of a series of 10 malignant peripheral nerve sheath tumors (MPNST) of the head and neck.
  • METHODS: From 1984 to 2004, 10 patients underwent surgical treatment of a MPNST.
  • RESULTS: Eight tumors were located at the lateral skull base; 2 involved the vagus nerve in isolation.
  • Negative prognostic indicators were advanced tumor stage, early recurrence, and presumably also the presence of von Recklinghausen's disease.
  • CONCLUSIONS: Although rare, MPNST is one of the most aggressive tumors in the head and neck area.
  • Complete tumor removal is the mainstay of treatment and most important prognostic factor of MPNST.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17163467.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


67. Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, Chugh R, Baker LH: Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist; 2008 Apr;13(4):459-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.
  • BACKGROUND: Synovial sarcomas (SnSrcs) and malignant peripheral nerve sheath tumors (MPNSTs) are rare mesenchymal tumors of adolescence and young adulthood.
  • METHODS: Tissue microarrays containing 48 cases of SnSrc and 32 cases of MPNST were stained for EGFR, EGFRvIII, and activated EGFR (pY1068-EGFR).
  • Tumor DNA was extracted from fresh and formalin-fixed, paraffin-embedded tissue blocks and sequenced for exons 17-21 of EGFR and exon 2 of K-ras and b-raf.
  • No K-ras or b-raf mutations were observed in either tumor type.
  • CONCLUSIONS: Expression of EGFR in SnSrcs and MPNSTs with an intact EGFR/mitogen-activated protein kinase pathway has been hypothesized to contribute to the malignant potential of these tumors.
  • [MeSH-major] Mutation. Nerve Sheath Neoplasms / diagnosis. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / genetics. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Genes, ras / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Proto-Oncogene Proteins B-raf / genetics. Translocation, Genetic


68. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M, Mautner VF: Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging; 2006 Apr;33(4):428-32
Genetic Alliance. consumer health - Peripheral type neurofibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
  • PURPOSE: In patients with neurofibromatosis type-1 (NF1) and malignant peripheral nerve sheath tumours (MPNSTs), survival rates are low and time to death is often less than 2 years.
  • Since histopathology and tumour grading are not well correlated with prognosis, we aimed to evaluate the potential of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) for prediction of patient outcome in MPNST.
  • [MeSH-major] Fluorodeoxyglucose F18. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / radionuclide imaging. Neurofibromatosis 1 / mortality. Neurofibromatosis 1 / radionuclide imaging. Positron-Emission Tomography / statistics & numerical data. Risk Assessment / methods
  • [MeSH-minor] Adolescent. Adult. Comorbidity. Female. Germany / epidemiology. Humans. Male. Middle Aged. Outcome Assessment (Health Care) / methods. Outcome Assessment (Health Care) / statistics & numerical data. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Risk Factors. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404595.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


69. Levi AD, Ross AL, Cuartas E, Qadir R, Temple HT: The surgical management of symptomatic peripheral nerve sheath tumors. Neurosurgery; 2010 Apr;66(4):833-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The surgical management of symptomatic peripheral nerve sheath tumors.
  • OBJECTIVE: To determine the clinical presentation and morbidity of the surgical management of peripheral nerve sheath tumors (PNSTs).
  • RESULTS: There were a total of 140 cases, including 87 schwannomas, 34 neurofibromas, and 19 malignant peripheral nerve sheath tumors (MPNSTs).
  • Tumor size was the best predictor of adverse outcome, as all MPNST mortalities occurred in patients with a tumor size of more than 7 cm.
  • [MeSH-major] Nerve Sheath Neoplasms / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Neurosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190660.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Landy H, Feun L, Markoe A, Patchen S, Bruce J, Marcus J, Levi A: Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report. J Neurosurg; 2005 Oct;103(4):760-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are difficult to control despite aggressive treatment.
  • In this report the authors describe the treatment and follow-up review of a patient with neurofibromatosis Type I who harbored a recurrent median nerve MPNST.
  • Two courses of preoperative intraarterial cisplatin and intravenous Adriamycin produced significant tumor shrinkage.
  • Gross-total removal of the remaining tumor without amputation of the arm was followed by fractionated radiotherapy (total minimum tumor dose 6485 cGy, maximal dose 6575 cGy).
  • The patient is alive 9.5 years after treatment without evidence of tumor recurrence and with only focal median nerve functional deficits.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Nerve Sheath Neoplasms / surgery. Neurofibromatosis 1 / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266062.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


71. Legbo JN, Shehu BB, Malami SA: Malignant peripheral nerve sheath tumour associated with von Recklinghausen's disease: case report. East Afr Med J; 2005 Jan;82(1):47-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumour associated with von Recklinghausen's disease: case report.
  • Only a few cases of malignant peripheral nerve sheath tumour (MPNST) associated with Von Recklinghausen's disease or type I neurofibromatosis (NF-1) have so far been reported worldwide, yet the primary disease (NF-I ) does not seem rare even in Africa.
  • We present a case of a 40 year old woman with MPNST of the left thigh associated with NF-1.
  • At surgery, a well localized soft tissue tumour, abutting on the sciatic nerve was widely resected without neural damage to the nerve.
  • It is presented to highlight the clinical and pathological features of NF-1 complicated with malignant transformation.
  • [MeSH-major] Nerve Sheath Neoplasms / etiology. Neurofibromatosis 1 / complications
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Forehead / innervation. Humans. Nigeria / epidemiology. Prognosis. Rare Diseases. Thigh / innervation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122112.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


72. Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ: [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging; 2009 May;36(5):751-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
  • PURPOSE: The detection of malignant peripheral nerve sheath tumours (MPNSTs) in patients with neurofibromatosis 1 (NF1) remains a clinical challenge.
  • The purpose of this study was to evaluate the use of [(18)F]2-fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT with early and delayed imaging) in patients with symptomatic neurofibromas, to revalidate current cut-off values for identification of malignant change within neurofibromas and to examine the relationship between SUV and tumour grade.
  • Sensitivity of FDG PET/CT in diagnosing NF1-associated MPNST was 0.97 (95% CI 0.81-0.99) and the specificity was 0.87 (CI 0.74-0.95).
  • There was a significant difference in SUVmax between early and delayed imaging and in SUVmax between tumours identified as benign and malignant on PET/CT.
  • CONCLUSION: FDG PET/CT is a highly sensitive and specific imaging modality for the diagnosis of MPNST in NF1 patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Humans. Middle Aged. Reproducibility of Results. Sensitivity and Specificity


73. Nabeshima K, Iwasaki H, Nishio J, Koga K, Shishime M, Kikuchi M: Expression of emmprin and matrix metalloproteinases (MMPs) in peripheral nerve sheath tumors: emmprin and membrane-type (MT)1-MMP expressions are associated with malignant potential. Anticancer Res; 2006 Mar-Apr;26(2B):1359-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of emmprin and matrix metalloproteinases (MMPs) in peripheral nerve sheath tumors: emmprin and membrane-type (MT)1-MMP expressions are associated with malignant potential.
  • However, their roles in peripheral nerve sheath tumors (PNSTs) have rarely been investigated.
  • MATERIALS AND METHODS: In this study, the immunohistochemical expression of 6 MMPs, their 3 inhibitors and emmprin, an MMP inducer, was examined in 14 schwannomas, 14 neurofibromas and 12 malignant peripheral nerve sheath tumors (MPNSTs) in relation to malignant potentials.
  • Moreover, the expression patterns of MMP-1 and gelatinase B (MMP-9) could divide PNSTs into two groups: schwannoma versus neurofibroma/MPNST.
  • CONCLUSION: These results suggest that emmprin and MT1-MMP may be malignant potential-related proteins in PNSTs, and that MMP-1 and 9 may help differentiation between schwannoma and neurofibroma, especially in their plexiform types.
  • [MeSH-major] Antigens, CD147 / biosynthesis. Matrix Metalloproteinases / biosynthesis. Nerve Sheath Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Male. Matrix Metalloproteinases, Membrane-Associated. Middle Aged. Neurilemmoma / enzymology. Neurilemmoma / metabolism. Neurilemmoma / pathology. Neurofibroma / enzymology. Neurofibroma / metabolism. Neurofibroma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619545.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Isoenzymes; 136894-56-9 / Antigens, CD147; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases, Membrane-Associated
  •  go-up   go-down


74. Shimada S, Tsuzuki T, Kuroda M, Nagasaka T, Hara K, Takahashi E, Hayakawa S, Ono K, Maeda N, Mori N, Illei PB: Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int; 2007 Feb;57(2):60-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression as a new marker in malignant peripheral nerve sheath tumors.
  • Malignant peripheral nerve sheath tumor (MPNST) can be difficult to diagnose because it lacks specific immunohistochemical markers.
  • S-100, which is a useful marker of MPNST, has limited diagnostic utility.
  • The diagnostic utility of immunostains for nestin and three other neural markers (S-100, CD56 and protein gene product 9.5 (PGP 9.5)) were evaluated in 35 cases of MPNST and in other spindle cell tumors.
  • All MPNST cases were strongly positive for nestin and had cytoplasmic staining.
  • Nestin was negative in 10/10 leiomyomas, and weak nestin expression was seen in 10/10 schwannomas, 3/10 neurofibromas, 2/8 synovial sarcomas, 2/10 liposarcomas, 4/7 carcinosarcomas and 3/7 malignant fibrous histiocytomas.
  • Nestin is more sensitive for MPNST than other neural markers and immunostains for nestin in combination with other markers could be useful in the diagnosis of MPNST.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Intermediate Filament Proteins / metabolism. Nerve Sheath Neoplasms / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cauda Equina / metabolism. Cauda Equina / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Child. Female. Gene Expression Regulation, Neoplastic. Humans. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Nestin. Neurilemmoma / metabolism. Neurilemmoma / pathology. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / pathology. Sarcoma / metabolism. Sarcoma / pathology. Schwann Cells / metabolism. Schwann Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300669.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


75. Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O: Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol; 2009 Sep;94(3):383-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of EGFR in malignant peripheral nerve sheath tumor.
  • Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma.
  • The study was aimed at investigating the expression and prognostic influence of EGFR in MPNST.
  • Forty-three percentage of 46 patients with MPNST overexpressed EGFR in the primary tumor, and had a higher prevalence of advanced-stage tumors (>or=IIc, 46% vs. 80%, P = 0.011).
  • EGFR appeared to play a role in MPNST progression.
  • Clinical trials of targeting EGFR in MPNST are warranted.
  • [MeSH-major] Nerve Sheath Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2009 Sep;94(3):389. Meimon, Natalie [corrected to Maimon, Natalie]
  • (PMID = 19330289.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


76. Okada K, Hasegawa T, Tajino T, Hotta T, Yanagisawa M, Osanai T, Nishida J, Seki K, Itoi E: Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol; 2007 Feb;14(2):597-604
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan.
  • BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is a relatively rare soft tissue tumor, and its clinical relevance of pathological grades remains obscure.
  • METHODS: Fifty-six cases of MPNST identified from the files of seven oncology centers of the Tohoku Musculoskeletal Tumor Society (TMTS) and National Cancer Center were analyzed for histologic grades, demographics, treatments, and prognostic factors.
  • Twenty-one (39.6%) of 53 patients who underwent tumor excision developed local recurrences.
  • Multivariate analysis revealed a large tumor and metastasis at presentation to be independent prognostic factors.
  • CONCLUSIONS: The current study involving 56 patients with MPNST showed the aggressive clinical behavior of the tumor.
  • In the treatment for a large and high-grade MPNST, an alternative strategy should be further considered.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Demography. Female. Humans. Japan. Male. Middle Aged. Prognosis. Societies, Medical. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103076.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


77. Nepka C, Karadana M, Karasavvidou F, Barbanis S, Kalodimos G, Koukoulis G: Fine needle aspiration cytology of a primary malignant peripheral nerve sheath tumor arising in the parotid gland: a case report. Acta Cytol; 2009 Jul-Aug;53(4):423-6
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a primary malignant peripheral nerve sheath tumor arising in the parotid gland: a case report.
  • BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is an uncommon mesenchymal neoplasm showing nerve sheath differentiation, usually arising in large nerves of the trunk and extremities.
  • We describe fine needle aspiration (FNA) findings in a case of MPNST in the parotid gland.
  • Smears were cellular, with clusters of tightly packed spindle or oval cells arranged in a storiform or whorled pattern, showing clearly malignant features.
  • The background contained abundant necrotic material with dispersed malignant nuclei.
  • Cytologic diagnosis was positive for malignant cells consistent with a spindle cell sarcoma, with morphologic features compatible to neural differentiation, confirmed by histologic examination.
  • CONCLUSION: This case illustrates that attention to moiphologic criteria suggestive of nerve sheath phenotype supported by immunocytochemical data is extremely helpful and reliable in the diagnostic approach to MPNSTs, even in rare locations.
  • [MeSH-major] Biopsy, Fine-Needle. Nerve Sheath Neoplasms / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2010 Sep-Oct;54(5 Suppl):1073-4 [21053609.001]
  • (PMID = 19697728.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Jeong SY, Park SJ, Lee SJ, Park HJ, Kim HJ: Loss of Y chromosome in the malignant peripheral nerve sheet tumor of a patient with Neurofibromatosis type 1. J Korean Med Sci; 2010 May;25(5):804-8
Genetic Alliance. consumer health - Peripheral type neurofibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Y chromosome in the malignant peripheral nerve sheet tumor of a patient with Neurofibromatosis type 1.
  • In order to determine whether genomic alterations and/or chromosomal aberrations involved in the malignant progression of NF1 were present in a Korean patient with NF1, molecular and cytogenetic analyses were performed on the pathologically normal, benign, and malignant tissues and primary cells cultured from those tissues of the patient.
  • The comparative genomic hybridization (CGH) array revealed a Y chromosome loss in the malignant peripheral nerve sheet tumor (MPNST) tissue.
  • G-banding analysis of 50 metaphase cells showed normal chromosomal patterns in the histopathologically normal and benign cultured cells, but a mosaic Y chromosome loss in the malignant cells.
  • The final karyotype for the malignant cells from MPNST tissue was 45,X,-Y[28]/46,XY[22].
  • [MeSH-major] Chromosomes, Human, Y / genetics. Nerve Sheath Neoplasms / genetics. Neurofibromatosis 1 / genetics
  • [MeSH-minor] Humans. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):11-6 [10564581.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):340-4 [11169957.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):122-7 [15066319.001]
  • [Cites] Cancer Lett. 2004 May 10;208(1):95-101 [15105051.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Am J Med Genet. 1999 Jun 11;84(5):413-9 [10360395.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):56-64 [16616112.001]
  • [Cites] Clin Genet. 2007 Nov;72(5):411-9 [17916097.001]
  • [Cites] Cytogenet Genome Res. 2007;119(1-2):158-64 [18160797.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Semin Ophthalmol. 2008 Jan-Feb;23(1):45-51 [18214791.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1329-32 [18684036.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):181-90 [10822134.001]
  • (PMID = 20436723.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2858846
  • [Keywords] NOTNLM ; CGH Array / Chromosome Loss / G-banding / Nerve Sheath Neoplasms / Neurofibromatosis 1, Y chromosome
  •  go-up   go-down


79. Li H, Zhang X, Fishbein L, Kweh F, Campbell-Thompson M, Perrin GQ, Muir D, Wallace M: Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells. Cancer Biol Ther; 2010 Oct 15;10(8):758-64
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.
  • The neurofibroma, a common feature of neurofibromatosis type 1 (NF1), is a benign peripheral nerve sheath tumor that contains predominantly Schwann cells (SC).
  • This study examined the effects of estrogen and progesterone on proliferation and apoptosis in a panel of NF1 tumor xenografts.
  • SC-enriched cultures derived from three human NF1 tumor types (dermal neurofibroma, plexiform neurofibroma, and malignant peripheral nerve sheath tumor (MPNST)) were xenografted in sciatic nerves of ovariectomized scid /Nf1-/+ mice.
  • Estrogen was found to increase the growth of all three MPNST xenografts.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Mol Cancer Res. 2009 Dec;7(12):2000-10 [19996302.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30740-5 [10900196.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):501-13 [11159187.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):97-105 [11244508.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):816-22 [12088451.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Feb;67(2):285-91 [20383709.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):752-5 [12591720.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):293-8 [12692193.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):758-63 [14514779.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):8-14 [14618609.001]
  • [Cites] Acta Neuropathol. 2004 Feb;107(2):159-68 [14673600.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1146-52 [14762442.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):405-9 [1698443.001]
  • [Cites] Acta Obstet Gynecol Scand. 1991;70(3):243-4 [1927303.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4261-4 [1322240.001]
  • [Cites] Brain Res Dev Brain Res. 1993 Apr 16;72(2):282-90 [8387406.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Clin Exp Metastasis. 1995 Jul;13(4):303-14 [7606893.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Apr;58(1):77-82 [8809188.001]
  • [Cites] Am J Med Genet. 1996 Dec 2;66(1):7-10 [8957502.001]
  • [Cites] EMBO Mol Med. 2009 Jul;1(4):236-48 [20049725.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):612-7 [9688181.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2820-8 [15571966.001]
  • [Cites] Horm Behav. 2005 Mar;47(3):350-7 [15708765.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Mar;157(2):181-6 [15721644.001]
  • [Cites] BMC Cancer. 2005 Feb 9;5:16 [15703081.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1080-8 [16319718.001]
  • [Cites] Exp Neurol. 2006 Jan;197(1):197-205 [16226751.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):716 [16786508.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] J Neurosci Res. 2007 May 1;85(6):1347-57 [17335073.001]
  • [Cites] Mol Carcinog. 2007 Jul;46(7):512-23 [17393410.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):2085-90 [17649826.001]
  • [Cites] Lab Invest. 2007 Nov;87(11):1092-102 [17876295.001]
  • [Cites] Dev Dyn. 2008 Feb;237(2):513-24 [18213578.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Clinics (Sao Paulo). 2008 Feb;63(1):39-42 [18297205.001]
  • [Cites] Am J Med Genet A. 2008 Jun 15;146A(12):1624-33 [18481270.001]
  • [Cites] Pediatr Res. 2008 Jul;64(1):40-3 [18360307.001]
  • [Cites] J Cutan Pathol. 2008 Nov;35(11):1014-9 [18547346.001]
  • [Cites] J Cell Biochem. 2009 Mar 1;106(4):553-62 [19160418.001]
  • [Cites] Neurogenetics. 2009 Jul;10(3):251-63 [19221814.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3149-55 [19661328.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6327-40 [19808870.001]
  • [Cites] Mol Carcinog. 2009 Nov;48(11):1005-17 [19479903.001]
  • [CommentIn] Cancer Biol Ther. 2010 Dec 1;10(11):1077-8 [20890125.001]
  • [CommentIn] Cancer Biol Ther. 2010 Oct 15;10(8):765-6 [20935464.001]
  • (PMID = 20699653.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / F30 NS043951; United States / NINDS NIH HHS / NS / 1F30NS43951
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Estrogens; 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  • [Other-IDs] NLM/ PMC3093914
  •  go-up   go-down


80. Bottillo I, Ahlquist T, Brekke H, Danielsen SA, van den Berg E, Mertens F, Lothe RA, Dallapiccola B: Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol; 2009 Apr;217(5):693-701
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.
  • Malignant peripheral nerve sheath tumours (MPNSTs) are a malignancy occurring with increased frequency in patients with neurofibromatosis type 1 (NF1).
  • In addition, DNA from peripheral blood and cutaneous neurofibroma biopsies from, respectively, 14/25 and 7/25 of the NF1 patients were analysed.
  • The spectrum of germline NF1 mutations in neurofibromatosis patients with MPNST is different from the spectrum of somatic mutations seen in MPNSTs.
  • [MeSH-major] Germ-Line Mutation. Nerve Sheath Neoplasms / genetics. Neurofibromatosis 1 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Chromatography, High Pressure Liquid / methods. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Point Mutation. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142971.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


81. Upadhyaya M, Spurlock G, Majounie E, Griffiths S, Forrester N, Baser M, Huson SM, Gareth Evans D, Ferner R: The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum Mutat; 2006 Jul;27(7):716
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs).
  • Malignant peripheral nerve sheath tumours (MPNSTs) are a major cause of mortality in patients with neurofibromatosis 1 (NF1).
  • Several studies have suggested that NF1 patients with a constitutional 1.5 Mb deletion of the NF1 gene have an increased risk of developing malignant peripheral nerve sheath tumours (MPNSTs).
  • Larger prospective studies are needed to ascertain whether there is a different spectrum of NF1 mutations in NF1 patients with high grade compared to low grade MPNSTs and of patients with the 1.5Mb deletion, in order to determine the true frequency of MPNST in this sub-group of NF1 patients.
  • [MeSH-major] Genes, Neurofibromatosis 1. Genetic Heterogeneity. Germ-Line Mutation. Nerve Sheath Neoplasms / genetics. Neurofibromatosis 1 / genetics
  • [MeSH-minor] Adolescent. Adult. DNA Mutational Analysis. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16786508.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Karube K, Nabeshima K, Ishiguro M, Harada M, Iwasaki H: cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol; 2006 Feb;59(2):160-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours.
  • BACKGROUND: Malignant peripheral nerve sheath tumour (MPNST) is a highly aggressive malignancy that arises within peripheral nerves, and is associated with poor prognosis.
  • Little is known about the underlying biology of MPNST, especially the mechanisms involved in cell proliferation, invasion, or escape from apoptosis.
  • AIMS: To identify genes differentially expressed in MPNST compared with benign tumours, such as neurofibromas and schwannomas, by means of cDNA microarray analysis.
  • METHODS: Six MPNST cases and five benign cases (three schwannomas and two neurofibromas) were analysed.
  • RESULTS: Six genes (keratin 18, survivin, tenascin C, adenosine deaminase, collagen type VIa3, and collagen type VIIa1) were significantly upregulated in MPNST, whereas one gene, insulin-like growth factor binding protein 6, was downregulated in MPNST.
  • Immunohistochemistry confirmed upregulation of survivin in MPNST at the protein level in six of eight cases compared with benign tumours.
  • Tenascin C was also expressed at the invasive front and tumorous stroma in all MPNST cases.
  • MPNST cells expressed tenascin C in four of nine cases.
  • CONCLUSIONS: Survivin and tenascin C may be associated with the malignant potential of MPNST and could be considered as potential therapeutic targets.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Nerve Sheath Neoplasms / metabolism. Peripheral Nervous System Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Profiling / methods. Humans. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / biosynthesis. Microtubule-Associated Proteins / genetics. Middle Aged. Neurilemmoma / genetics. Neurilemmoma / metabolism. Neurilemmoma / pathology. Neurofibroma / genetics. Neurofibroma / metabolism. Neurofibroma / pathology. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction / methods. Tenascin / biosynthesis. Tenascin / genetics. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 1999 Dec;1(8):461-6 [10587640.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):648-57 [1991849.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):1-9 [10699960.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:127-30 [10707794.001]
  • [Cites] Growth Horm IGF Res. 2000 Dec;10(6):349-59 [11161966.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):965-9 [11581297.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):636-43 [1712747.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Growth Regul. 1991 Sep;1(3):125-30 [1726837.001]
  • [Cites] Annu Rev Physiol. 1993;55:131-53 [8466170.001]
  • [Cites] Cell Biol Int. 1993 Mar;17(3):325-9 [7685649.001]
  • [Cites] Pathol Res Pract. 1994 Apr;190(4):412-5 [8078812.001]
  • [Cites] Experientia. 1995 Sep 29;51(9-10):853-62 [7556567.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4522-9 [8813151.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1879-85 [9816144.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5071-4 [9823313.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):120-4 [15611790.001]
  • [Cites] Trends Mol Med. 2001 Dec;7(12):542-7 [11733216.001]
  • [Cites] Diagn Mol Pathol. 2002 Mar;11(1):33-40 [11854600.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] J Pathol. 2002 Jul;197(3):388-94 [12115886.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Histopathology. 2003 Mar;42(3):280-91 [12605648.001]
  • [Cites] J Neurooncol. 2003 May;62(3):321-8 [12777085.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):706-12 [12866030.001]
  • [Cites] Clin Exp Dermatol. 2003 Sep;28(5):515-20 [12950343.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1019-27 [14559985.001]
  • [Cites] BMC Dev Biol. 2001;1:5 [11305929.001]
  • [Cites] J Pathol. 2003 Nov;201(3):430-8 [14595755.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):529-38 [14767537.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Cell. 1990 Jul 13;62(1):187-92 [1694727.001]
  • [Cites] Science. 1990 Jul 13;249(4965):181-6 [2134734.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):617-23 [10698506.001]
  • (PMID = 16443732.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1860323
  •  go-up   go-down


83. Mantripragada KK, Díaz de Ståhl T, Patridge C, Menzel U, Andersson R, Chuzhanova N, Kluwe L, Guha A, Mautner V, Dumanski JP, Upadhyaya M: Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. Genes Chromosomes Cancer; 2009 Oct;48(10):897-907
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array.
  • Neurofibromatosis Type I (NF1) is an autosomal dominant disorder characterized by the development of both benign and malignant tumors.
  • The lifetime risk for developing a malignant peripheral nerve sheath tumor (MPNST) in NF1 patients is approximately 10% with poor survival rates.
  • To date, the molecular basis of MPNST development remains unclear.
  • Here, we report the first genome-wide and high-resolution analysis of DNA copy number alterations in MPNST using the 32K bacterial artificial chromosome microarray on a series of 24 MPNSTs and three neurofibroma samples.
  • The profiles of malignant samples, however, revealed specific loss of chromosomal regions including 1p35-33, 1p21, 9p21.3, 10q25, 11q22-23, 17q11, and 20p12.2 as well as gain of 1q25, 3p26, 3q13, 5p12, 5q11.2-q14, 5q21-23, 5q31-33, 6p23-p21, 6p12, 6q15, 6q23-q24, 7p22, 7p14-p13, 7q21, 7q36, 8q22-q24, 14q22, and 17q21-q25.
  • Copy number gains were more frequent than deletions in the MPNST samples (62% vs. 38%).
  • [MeSH-major] Comparative Genomic Hybridization / methods. Genes, Neurofibromatosis 1. Nerve Sheath Neoplasms / genetics. Neurofibromatosis 1 / genetics. Oligonucleotide Array Sequence Analysis / methods. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosomes, Artificial, Bacterial. Female. Gene Dosage. Genome, Human. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19603524.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Oda S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M: Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients. Cancer Genet Cytogenet; 2006 Mar;165(2):98-105
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients.
  • Malignant peripheral nerve sheath tumor (MPNST) is an uncommon soft tissue neoplasm with a poor prognosis, occurring sporadically or associated with neurofibromatosis type 1 (NF1); however, the histogenesis of MPNST remains unclear, especially in sporadic tumors.
  • To elucidate the chromosomal aberration as a consequence of CIN and MSI status of MPNST, we karyotyped 10 MPNSTs from nine patients, and examined the MSI of seven microsatellite markers using high-resolution fluorescence microsatellite analysis; 2 out of 10 cases (20%) had normal karyotypes, and 8 out of 10 cases (80%) revealed structural and numerical chromosomal aberrations.
  • These findings suggest that chromosomal aberration as a consequence of CIN has a greater role in the pathogenesis of MPNST than does that due to MSI.
  • [MeSH-major] Chromosome Aberrations. Microsatellite Repeats / genetics. Nerve Sheath Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Karyotyping. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527603.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, Ruggieri M, Chuzhanova N, Evans DG, Ferner R, Thomas N, Guha A, Mautner V: Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat; 2008 Jan;29(1):74-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).
  • About 10% of neurofibromatosis type 1 (NF1) patients develop malignant peripheral nerve sheath tumors (MPNSTs) and represent considerable patient morbidity and mortality.
  • Elucidation of the genetic mechanisms by which inherited and acquired NF1 disease gene variants lead to MPNST development is important.
  • The NF1 germline mutation spectrum was similar to that previously identified in adult NF1 patients without MPNST.
  • Somatic NF1 mutations were identified in tumor DNA from 31 out of 34 MPNSTs, of which 28 were large genomic deletions.
  • The high prevalence (>90%) of such deletions in MPNST contrast with the =or<20% found in benign neurofibromas and is indicative of the involvement of different mutational mechanisms in these tumors.
  • [MeSH-major] Germ-Line Mutation. Mutation. Nerve Sheath Neoplasms / genetics. Neurofibromin 1 / genetics. Peripheral Nervous System Neoplasms / genetics
  • [MeSH-minor] Adult. DNA Mutational Analysis. DNA, Neoplasm / metabolism. Humans. Loss of Heterozygosity. Lymphocytes / metabolism. Sequence Deletion. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960768.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


86. Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM: Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol; 2008 Aug;10(4):593-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
  • People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs).
  • Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST.
  • Both the median number of plexiform neurofibromas (p < 0.05) and the median neurofibroma volume (p < 0.01) on whole-body MRI were significantly greater among MPNST patients younger than 30 years of age than among controls.
  • Whole-body imaging of young NF1 patients may allow those at highest risk for developing MPNST to be identified early in life.
  • [MeSH-major] Magnetic Resonance Imaging. Neurofibromatosis 1 / pathology. Tumor Burden. Whole Body Imaging
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7 [10675220.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):562-70; discussion 571-2, 646-51 [12403554.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):573-7; discussion 602-4, 646-51 [12403555.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1288-92 [12660952.001]
  • [Cites] Hum Mutat. 2003 Nov;22(5):420 [14517963.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):111-6 [14722914.001]
  • [Cites] Am J Hum Genet. 2004 Sep;75(3):410-23 [15257518.001]
  • [Cites] Brain. 2004 Sep;127(Pt 9):1993-2009 [15289270.001]
  • [Cites] Surg Gynecol Obstet. 1983 May;156(5):636-40 [6405495.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):78-83 [8259105.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):78-82 [7851559.001]
  • [Cites] Arch Pathol Lab Med. 1997 Feb;121(2):139-43 [9126041.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Neurology. 1998 Jun;50(6):1755-60 [9633723.001]
  • [Cites] Neuroradiology. 1999 Sep;41(9):625-9 [10525761.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):837-41 [15520408.001]
  • [Cites] Am J Med Genet A. 2005 Jan 1;132A(1):49-53 [15523617.001]
  • [Cites] Hum Genet. 2005 May;116(6):466-75 [15776250.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1699-702 [16033085.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):205-11 [16043787.001]
  • [Cites] J Surg Orthop Adv. 2005 Winter;14(4):168-74 [16442014.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32 [16404595.001]
  • [Cites] Semin Pediatr Neurol. 2006 Mar;13(1):2-7 [16818170.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):233-8 [16786042.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):643-7 [17215493.001]
  • [Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]
  • [Cites] Neurosurg Focus. 2007;22(6):E12 [17613203.001]
  • [Cites] Neurosurg Focus. 2007;22(6):E3 [17613220.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1957-60 [17649804.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):928-35 [17885067.001]
  • [Cites] Ann Dermatol Venereol. 2007 Oct;134(10 Pt 1):735-41 [17978710.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):390-4 [17932395.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Arch Pediatr. 2002 Jan;9(1):49-60 [11865551.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):555-61; discussion 571-2, 646-51 [12403553.001]
  • (PMID = 18559970.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2666233
  •  go-up   go-down


87. Molina AR, Brasch H, Tan ST: Malignant peripheral nerve sheath tumour of the cervical vagus nerve in a neurofibromatosis type 1 patient. J Plast Reconstr Aesthet Surg; 2006;59(12):1458-62
Genetic Alliance. consumer health - Peripheral type neurofibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumour of the cervical vagus nerve in a neurofibromatosis type 1 patient.
  • One serious complication of neurofibromatosis type 1 (NF1) is the development of malignant peripheral nerve sheath tumours (MPNSTs).
  • Recent work demonstrates that the lifetime risk of malignant transformation is significantly greater than previously thought.
  • We present an NF1 patient who developed an MPNST of the cervical vagus nerve which was successfully treated with surgery.
  • Close monitoring of patients with NF and a high level of suspicion towards rapidly enlarging and painful swellings is merited as these features may signify malignant transformation.
  • Whether a positive history of MPNST in other affected family members predisposes the individual to a higher risk of malignant transformation is unclear.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / pathology. Vagus Nerve. Vagus Nerve Diseases / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113542.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


88. Storlazzi CT, Brekke HR, Mandahl N, Brosjö O, Smeland S, Lothe RA, Mertens F: Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol; 2006 Aug;209(4):492-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours.
  • Previous studies have suggested that amplification of genes, notably the TOP2A gene, on chromosome arm 17q may be important for the development of malignant peripheral nerve sheath tumour (MPNST).
  • Increased copy numbers were seen for the ERBB2 and TOP2A genes in eight and nine cases, respectively, supporting a potential role for these two genes in MPNST tumourigenesis.
  • Among the genes mapping to this region, BIRC5, which encodes the baculoviral IAP repeat-containing protein 5/survivin protein, is a strong candidate target gene for amplification, as it has been previously shown to be overexpressed in neurofibromatosis type 1-associated MPNST.
  • Three other genes that co-amplified with BIRC5 represent other potential candidate genes: PTDSR involved in apoptosis; SEPT9 overexpressed in human malignant brain tumours; and SOCS3 involved in cell survival and differentiation of neurons.
  • [MeSH-major] Chromosomes, Human, Pair 17. Genes, Neoplasm. Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Nerve Sheath Neoplasms / genetics. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Chromosome Banding. DNA Topoisomerases, Type II / genetics. Female. Follow-Up Studies. Gene Amplification. Gene Dosage. Genes, erbB-2. Humans. In Situ Hybridization, Fluorescence. Inhibitor of Apoptosis Proteins. Interphase. Male. Metaphase. Middle Aged. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16721726.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


89. Kretschmer T, Antoniadis G, Heinen C, Börm W, Scheller C, Richter HP, Koenig RW: Nerve sheath tumor surgery: case-guided discussion of ambiguous findings, appropriateness of removal, repeated surgery, and nerve repairs. Neurosurg Focus; 2007;22(6):E19
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve sheath tumor surgery: case-guided discussion of ambiguous findings, appropriateness of removal, repeated surgery, and nerve repairs.
  • In this article the authors attempt to raise awareness of the pitfalls and controversial issues in nerve tumor surgery.
  • In a case-guided format, examples of ambiguous findings, inappropriate tumor removal, repeated surgery, and nerve repairs are provided.
  • The authors also discuss the need to establish a correct diagnosis preoperatively and to avoid the erroneous identification of malignant peripheral nerve sheath tumors (MPNSTs).
  • They emphasize that not all of the principles of soft tissue sarcoma treatment protocols are applicable to MPNST.
  • A situation of repeated surgery for supposedly malignant tumor is described, and an outline of the indications for, and an approach to, repair after lesion removal is given.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / surgery. Neurosurgical Procedures / methods. Peripheral Nerve Injuries. Peripheral Nerves / surgery. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Reoperation / adverse effects. Reoperation / methods

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613210.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


90. Sanchez-Mejia RO, Pham DN, Prados M, Tihan T, Cha S, El-Sayed I, McDermott MW: Management of a sporadic malignant subfrontal peripheral nerve sheath tumor. J Neurooncol; 2006 Jan;76(2):165-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of a sporadic malignant subfrontal peripheral nerve sheath tumor.
  • Malignant subfrontal (olfactory) peripheral nerve sheath tumors (MPNSTs) are exceedingly rare.
  • In this paper, we describe a patient with a subfrontal MPNST with unusual histological characteristics and present a review of the literature.
  • The patient underwent both a bifrontal transbasal craniotomy and a transnasal approach for an attempt at total resection of both the intradural and extradural components of the MPNST.
  • The specific cell and nerve of origin for these tumors remains unknown.
  • Our case shows that these rare lesions can present as a malignant variant and thus require aggressive surgical and postoperative management to provide long-term tumor control.
  • [MeSH-major] Brain Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Craniotomy. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Olfaction Disorders / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132491.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Thomas C, Somani N, Owen LG, Malone JC, Billings SD: Cutaneous malignant peripheral nerve sheath tumors. J Cutan Pathol; 2009 Aug;36(8):896-900
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignant peripheral nerve sheath tumors.
  • Cutaneous malignant peripheral nerve sheath tumors (MPNSTs) are rare entities compared with their deep soft tissue counterparts.
  • The second case presented in an 88-year-old man with no stigmata of neurofibromatosis as a rapidly growing subcutaneous tumor of the right calf.
  • The diagnosis of MPNST was rendered in both cases.
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Male. Mitosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586501.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


92. Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR: Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol; 2007 Oct;189(4):928-35
Hazardous Substances Data Bank. (L)-Methionine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of our study was to investigate the use of PET in the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1 (NF1).
  • MATERIALS AND METHODS: Forty-five patients with NF1 who underwent whole-body PET for suspected MPNST based on clinical symptoms or radiologic examinations were retrospectively evaluated.
  • PET may improve preoperative tumor staging by detecting metastases or second primary tumors, which often are present in patients with NF1.
  • [MeSH-major] Fluorodeoxyglucose F18. Methionine / deficiency. Neurofibromatosis 1 / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Isotopes. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885067.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


93. Jokinen CH, Argenyi ZB: Atypical neurofibroma of the skin and subcutaneous tissue: clinicopathologic analysis of 11 cases. J Cutan Pathol; 2010 Jan;37(1):35-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neurofibroma (NF) is a relatively common cutaneous tumor, which typically presents little diagnostic difficulty.
  • Occasionally, however, pleomorphic cells may be present in NF raising consideration of other neoplasms like malignant peripheral nerve sheath tumor (MPNST).
  • Some tumors were hypercellular, but marked density characteristic of MPNST was not observed.
  • Of six patients with available follow-up, no tumor recurred and none developed malignancy (range 6-63, mean 33 months).
  • CONCLUSIONS: Superficial atypical NF, while morphologically unusual, has no apparent association with neurofibromatosis-1 or short-term risk of recurrence or malignant transformation.
  • Awareness of this variant is important in order to avoid misdiagnosis of a more aggressive neoplasm.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Nerve Sheath Neoplasms / pathology. S100 Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Neurofibroma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 19469864.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


94. Zheng L, Zhang JG, Yu GY, Gao Y: [Malignant peripheral nerve sheath tumors in oral maxillofacial region: clinical analysis of 11 cases]. Beijing Da Xue Xue Bao; 2010 Apr 18;42(2):216-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peripheral nerve sheath tumors in oral maxillofacial region: clinical analysis of 11 cases].
  • OBJECTIVE: To investigate the clinicopathologic features, treatment and prognosis of the malignant peripheral nerve sheath tumors (MPNST) in oral and maxillofacial region.
  • CONCLUSION: MPNST is one of the most aggressive tumors with high risk of local recurrence and distant metastasis.
  • Complete removal of the tumor is the main modality of treatment and a most important prognostic factor of MPNST.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Maxillary Neoplasms / diagnosis. Mouth Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396368.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


95. Hatori M, Hosaka M, Watanabe M, Moriya T, Sasano H, Kokubun S: Osteosarcoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Tohoku J Exp Med; 2006 Apr;208(4):343-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant tumors of the nervous system, such as malignant schwannomas, gliomas, or astrocytomas, have been well known to coexist with neurofibromatosis.
  • However, occurrence of malignant tumors unrelated to the nervous system is rare.
  • We report an unusual case of a 29-year-old NF1 female suffering from malignant peripheral nerve sheath tumor (MPNST) that eventually developed osteosarcoma in the proximal femur.
  • Osteosarcoma is the most common high-grade malignant bone tumor in which the neoplastic cells produce osteoid.
  • At 23 and 24 years old, she underwent excision of MPNST in the left posterior thigh.
  • Computed tomography demonstrated cortical bone destruction in the left proximal femur where MPNST occurred.
  • Magnetic resonance imaging revealed extraskeletal growth of the tumor.
  • The removed tumor was composed of highly anaplastic cells.
  • Lace-like irregular osteoid formation was observed among the tumor cells.
  • MPNST component was totally absent.
  • The tumor was diagnosed as osteoblastic type osteosarcoma.
  • The correlation between the histogenesis of osteosarcoma and the genetic abnormality in NF1 patients has not been elucidated, but the finding of osteosarcomatous transformation in this case suggests the divergent cellular differentiation to mesenchymal malignant tumors of neuroectodermal tissue in NF1 patients.
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Combined Modality Therapy. Fatal Outcome. Female. Femur / pathology. Femur / radiography. Humans. Magnetic Resonance Imaging. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / therapy


96. Longhi A, Errani C, Magagnoli G, Alberghini M, Gambarotti M, Mercuri M, Ferrari S: High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature. J Chemother; 2010 Dec;22(6):413-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature.
  • Malignant peripheral nerve sheath tumours (MPNST) are rare sarcomas with one of the poorest prognoses of all the soft tissue sarcomas.
  • We analyzed retrospectively the outcome of patients with localized high grade MPNST admitted to our institute from 1969 to 2008.
  • New drugs employed successfully in advanced mpNSt should be employed also in the adjuvant setting.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21303750.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


97. Okoshi A, Shiga K, Sasaki K, Asada Y, Nishikawa H, Kobayashi T, Watanabe M: [Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):533-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma].
  • We report two cases of radiation-induced sarcoma after chemoradiation therapy in nasopharyngeal carcinoma.
  • Case 1: A 40-year-old man developed a malignant peripheral nerve sheath tumor (MPNST) in the posterior floor of the nasal cavity 10 years after treatment for nasopharyngeal cancer.
  • Case 2: A 64 year-old man developed a malignant fibrous histiocytoma (MFH) of the lower gum 10 years after treatment of nasopharyngeal cancer.
  • Despite radical surgery, the man with MPNST had a recurrent tumor and died of the disease.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / etiology. Nasopharyngeal Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Nerve Sheath Neoplasms / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697477.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


98. Ghosh A, Talwar OP, Pradhan SV: Tumour and tumour-like conditions of peripheral nerve origin: ten years' experience. Kathmandu Univ Med J (KUMJ); 2010 Jan-Mar;8(29):97-101
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour and tumour-like conditions of peripheral nerve origin: ten years' experience.
  • BACKGROUND: There are four major lesions which may arise in the peripheral nerve, namely neuroma, schwannoma, neurofibroma and malignant peripheral nerve sheath tumor.
  • OBJECTIVE: In the present study we look into the spectrum of peripheral neural tumors including their age distribution site distribution and histopathology.
  • All histopathologically diagnosed cases of primary lesions of peripheral nerve during the period Jan 2000 to Nov 2009 were reviewed and the data were analysed.
  • RESULT: A total of 114 cases of peripheral neural lesions were reported in the same period.
  • Total number of nonmalignant cases was 106 (93%) while malignant cases were 8 (7%).
  • Among the nonmalignant cases neurofibroma was the commonest (51 cases, 45% of all) closely followed by schwannoma (39 cases, 34% of all).
  • Among the schwannoma cases 4 were diagnosed as ancient schwannoma with presence of bizarre cells with hyperchromatic nuclei.
  • The commonest site involved for both schwannoma and neurofibroma was scalp-face-neck followed by back.
  • The age range for schwannoma was 16 to 75 years whereas the same for the neurofibroma cases was 2 to 82 years.
  • MPNST cases were seen in the age range of 40 to 72 with 3 cases in upper extremity, 3 in lower extremity and 1 each in lip and cheek.
  • CONCLUSION: The majority of the tumor are benign and the commonest benign tumor was neurofibroma of sporadic type, closely followed by schwannoma.
  • [MeSH-major] Nerve Sheath Neoplasms / epidemiology. Neurilemmoma / epidemiology. Neurofibroma / epidemiology. Neuroma / epidemiology. Peripheral Nervous System Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21209517.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


99. Spurlock G, Griffiths S, Uff J, Upadhyaya M: Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam Cancer; 2007;6(4):463-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types.
  • We have carried out NF1 gene mutation analysis on DNA isolated from 25 tumours (dermal and plexiform neurofibromas, malignant peripheral nerve sheath tumour, MPNST), obtained at post-mortem from an NF1 patient.
  • [MeSH-minor] Adolescent. Adult. Alleles. Base Sequence. Child, Preschool. Chromatography, High Pressure Liquid. Exons / genetics. Gene Deletion. Humans. Microsatellite Instability. Molecular Sequence Data. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


100. Hui P, Li N, Johnson C, De Wever I, Sciot R, Manfioletti G, Tallini G: HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor. Mod Pathol; 2005 Nov;18(11):1519-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor.
  • Histological separation of synovial sarcomas from malignant peripheral nerve sheath tumors can be difficult and available immunohistochemical markers sometimes give rise to overlapping staining patterns.
  • To this end, we explored diagnostic applications of HMGA (HMGA1 and HMGA2) protein immunohistochemistry in comparable groups of synovial sarcoma and malignant peripheral nerve sheath tumors.
  • The histological diagnosis of these cases was confirmed by the presence or absence of synovial sarcoma specific SYT-SSX fusion transcript analyzed by real-time reverse transcription polymerase chain reaction.
  • In all, 13 malignant peripheral nerve sheath tumors and 15 synovial sarcomas were included in this study.
  • Immunohistochemically, most malignant peripheral nerve sheath tumors expressed both HMGA1 and HMGA2 protein (12/13 and 12/13 cases, respectively) with moderate to strong nuclear staining patterns.
  • However, significant immunoreactivity for HMGA2 was present in the glandular component of a biphasic tumor (1/1) and rarely detected in monophasic synovial sarcomas (1/14).
  • In summary, expression of HMGA2 is a feature of MPNST but not of synovial sarcoma and immunohistochemical staining of HMGA2 may be a useful marker to separate malignant peripheral nerve sheath tumor from synovial sarcoma.
  • [MeSH-major] HMGA Proteins / biosynthesis. Nerve Sheath Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Modern Pathology (2005) 18, 1519-1526. doi:10.1038/modpathol.3800464; published online 29 July 2005.
  • (PMID = 16056249.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA Proteins; 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  •  go-up   go-down






Advertisement